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Pulmonary surfactant is a surface active lipidprotein complex covering the air
liquid interface at the surface of the alveoli in the lungs. Its main function is to reduce
the surface tension at the interface, and thus to minimize the work of breathing and
prevent the alveoli from collapsing at the end of the breathing cycle. Pulmonary
surfactant protein B (SP-B) is an essential protein, necessary for the formation and
maintaining of the ﬁlm at the interface. Despite its importance, there has been
no structural model for SP-B, or information about its molecular mechanism of
function.
In this thesis, we study the speciﬁc lipid interactions and membrane binding
conformations of our new reﬁned model for the SP-B hexamer of dimers. We use
molecular dynamics simulations with the coarse-grained MARTINI force ﬁeld for
spontaneous lipid self-assembly and monolayer studies with SP-B. We concentrate
on speciﬁc protein-lipid interactions, lateral lipid reorganization, and perturbations
caused by SP-B in membranes.
The results show speciﬁc lipid interaction sites in the structure of SP-B. We
found that the protein causes lateral reorganization of lipids in monolayers and
shows speciﬁcity towards phosphatidylglycerol and cholesterol. We further found
that SP-B as a hexamer of dimers has speciﬁc membrane binding residues that orient
the protein parallel to the surface of the membrane. SP-B causes lipid protrusions
in monolayers and membranes. These results imply a molecular mechanism for lipid
transfer through a SP-B oligomer ring in the surfactant.
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Keuhkosurfaktantti on pinta-aktiivinen lipoproteiinikompleksi keuhkorakkuloiden
ilmavesi-rajapinnassa. Sen tärkein tehtävä on alentaa keuhkorakkuloiden pintajän-
nitystä ja siten vähentää hengittämiseen tarvittavaa työtä sekä estää keuhkorakku-
loiden kasaanpainuminen uloshengityksen aikana. Keuhkosurfaktanttiproteiini B
(SP-B) on elintärkeä proteiini, jota tarvitaan surfaktanttikalvon muodostumiseen
ja ylläpitämiseen keuhkorakkuloiden pinnalle. Huolimatta SP-B:n välttämättömyy-
destä, sille ei ole ollut rakenteellista mallia tai molekyylitason toimintamekanismia.
Tässä työssä tutkittiin uuden kuudesta dimeeristä koostuvan oligomeerisen SP-B
proteiinimallin lipidi-vuorovaikutuksia sekä proteiinin sitoutumista lipidikalvoihin.
Tähän tarkoitukseen sovelsimme molekyylidynamiikkasimulaatioita käyttäen karkeis-
tettua MARTINI-voimakenttää, jonka avulla tutkimme lipidien spontaania aggregoi-
tumista ja monomolekulaarisia lilidikalvoja SP-B:n kanssa. Keskityimme pääasiassa
SP-B:lle ominaisiin proteiinilipidi -vuorovaikutuksiin, lipidien uudelleenjärjestymi-
seen kalvoissa sekä SP-B:n aiheuttamiin häiriöhin lipidikalvoissa.
Tutkimuksessa havaittiin SP-B:n rakenteessa olevan erityisiä lipidivuorovaikutu-
spaikkoja. Proteiini aiheutti lipidien uudelleenjärjestymistä lipidikalvoissa, ja se os-
oitti sitoutumisspesiﬁsyyttä erityisesti fosfatidyyliglyserolia ja kolesterolia kohtaan.
SP-B-oligomeerissa on membraaneihin sitoutumisen kannalta tärkeitä aminohap-
poja, jotka suuntaavat proteiinin yhdensuuntaisesti kalvon pinnan suhteen. SP-B ai-
heutti rakenteellisia muutoksia lipidikalvoihin. Nämä tulokset viittaavat molekyyli-
tason toimintamalliin, jossa lipidit siirtyvät kalvolta toiselle kulkien SP-B-oligomeeri-
renkaan läpi.
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11. INTRODUCTION
The respiratory surface of the lungs is covered by the pulmonary surfactant, a surface
active ﬁlm composed of membrane structures and surfactant proteins [1]. The main
function of the surfactant is to optimize breathing by reducing the surface tension
at the alveolar airwater interface, thus preventing the collapse of the alveoli during
the compressionexpansion cycles [2,3]. Pulmonary surfactant has also been shown
to accelerate the diﬀusion of oxygen through the airliquid interface [4].
As air is inhaled through the nose or the mouth, it ﬁrst travels through the
conducting zone of the respiratory system consisting of the pharynx, larynx, trachea,
and the bronchi and bronchioles in the lungs (see Fig. 2.1). After many steps of
bifurcation into smaller and smaller branches of the respiratory tree, the air ends
up into the respiratory zone of the lungs. Alveoli are located at the end of the
respiratory tree. They are the main gas exchange zone in the lungs, where the
oxygen in the air is passed through the pulmonary surfactant covering the surface
of the thin water phase, which in turn covers the respiratory epithelium. Together
with the surfactant speciﬁc proteins, the pulmonary surfactant has a biologically
unique phospholipid composition that makes it able to sustain high surface pressures
without collapsing [2].
Pulmonary surfactant protein B (SP-B) is an essential part of the pulmonary sur-
factant. It participates in the interfacial adsorption of phospholipids, ﬁlm stability,
and surfactant re-spreading [3]. SP-B is a 79-residue polypeptide that forms a cova-
lent homodimer. Due to the high hydrophobicity and diﬃculty of extraction, there
has been no model for the structure or knowledge of the mechanism of function of
SP-B [5]. Previous structural models for monomers and dimers of SP-B have been
based on homology modeling with diﬀerent saposin-like proteins (SAPLIPs) [5], but
they have not provided unambiguous models that would explain all experimental
results [6]. In this study, we have reﬁned a recently published model for the new
oligomeric 3D structure of SP-B [6].
Lung immaturity caused by premature birth or mutations in the genes coding for
SP-B leads to a condition called respiratory distress syndrome (RDS) [7,8], which is
one of the leading causes of neonatal deaths in the world [9]. RDS can be eﬀectively
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treated with surfactant replacement therapy (SRT), but its relatively high cost limits
its use in low-income countries. Common clinical surfactants used for the treatment
of SRT are derived from animal sources [10]. The development of a more aﬀordable
treatment based on synthetic surfactants would therefore be of interest. SP-B or its
structurally analogous synthetic counterparts like Mini-B [11], have been shown to
have a key role in the functionality of clinical surfactants [10].
Understanding the molecular mechanism of function of SP-B could provide vital
information of this essential protein and give us ways to develop new drugs and
treatments for conditions like RDS or acute respiratory distress syndrome (ARDS)
in adults. The possible indirect involvement of SP-B in the transfer of oxygen
across the pulmonary surfactant [4] could change our current view on the details of
gas exchange in the alveoli. Traditional experimental methods can not achieve the
molecular level of detail needed for the study of nanometer scale of size systems or
reactions that occur within nanosecond timescales.
In this study, we utilized coarse-grained molecular dynamics (MD) simulations to
study the molecular mechanism of function of our new model for the SP-B hexamer
of dimers. MD simulations enable atomistic or near atomistic level of detail of
biological systems, and insight to phenomena occurring therein. We concentrated
on the speciﬁc lipid interactions of the protein to ﬁnd preferential lipid binding
conformations for SP-B. We also compared diﬀerent versions of the SP-B dimer
to the SP-B hexamer of dimers to validate the possibility of the higher oligomer
structures, and see how their possible molecular mechanism of function diﬀers from
each other. We built a total of 9 × 24 lipid self-assembly (SA) systems starting
from a random initial conﬁguration with three lipid compositions, and 48 monolayer
systems with a lipid composition resembling the physiological structure of pulmonary
surfactant at the airliquid interface.
This thesis is divided into seven chapters. Chapter 2 focuses on the biological
background relevant to understanding the human respiratory system and SP-B.
The general concepts of the classical molecular dynamics simulations and the coarse-
grained MARTINI force ﬁeld used in this study are discussed in chapter 3. Chapter 4
gives a short introduction to protein structure prediction methods that can be used
to model the structures of novel proteins. Simulation models and analysis methods
used in this study are introduced in chapter 5. Chapter 6 covers the most relevant
results. Finally, the conclusions in chapter 7 summarize the key results and future
prospects.
32. BIOLOGICAL BACKGROUND
In this chapter the biological background relevant to this study is discussed. First
the overview of the human respiratory system describes the general structural and
functional features characteristic to the mammalian lung. Then a short insight to
the main structures making up the pulmonary surfactant is given. The chapter is
ﬁnalized with a discussion about the most important surfactant protein, and the
emphasis of this study, the pulmonary surfactant protein B.
2.1 Overview of the Human Respiratory System
The cardiovascular and respiratory systems are responsible for the supply of neces-
sary oxygen (O2) for aerobic cell respiration, as well as the disposal of waste carbon
dioxide (CO2) from the body [12, 13]. The cardiovascular system consists of the
heart, blood, and the blood vessels while the respiratory system consists of the up-
per and the lower respiratory tracts (see Fig. 2.1). The continuous transport of
O2 and CO2 between the lungs and the tissues is carried out by the cardiovascular
system which pumps the oxygenated blood from the lungs to the rest of the body.
In addition to the exchange of gases in the lungs the respiratory system has an im-
portant role in the immune system, heat exchange, ﬂuid balance, and pH control of
the whole body [14].
The human respiratory system can be divided into the conducting zone and the
respiratory zone based the function of the structures. The main function of the
conducting zone is to humidify, warm, and ﬁlter the inhaled air before it reaches the
respiratory zone that is responsible for the gas exchange [15]. Pretreatment of the
inhaled air before the alveoli prevents infections, the transport of harmful substances
and particles into the respiratory zone, and the drying of the gas exchange interface.
Inhaled air is relatively dry and cool, while exhaled air is heated up to the body
temperature and saturated with water vapor [14]. The most important role of the
lungs is the exchange of gases between the air and the transporter liquid (blood),
which takes place in the respiratory zone.
Air is inhaled through the nose or the mouth, from where it travels through the
pharynx, larynx, and the trachea (windpipe). The trachea divides into two primary
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Figure 2.1 Structure of the human lungs. Left: the conducting zone of the respira-
tory system. Right: a close-up of the respiratory zone including a respiratory bronchiole,
alveolar ducts, and alveoli. Modiﬁed from [16].
bronchi that continue to bifurcate systematically into smaller and smaller bronchi
and bronchioles [14]. After many steps of bifurcation, at the end of the conducting
zone the air reaches the terminal bronchioles that divide into respiratory bronchioles
that ﬁnally lead to the alveolar ducts and the main gas exchange zone in the alveoli
(see Fig. 2.1) [13, 14]. The process of gas ﬂow between the atmosphere and the
lung alveoli is called pulmonary ventilation [12]. In inhalation air is drawn into
the respiratory zone by expanding the volume of the lungs and creating a negative
pressure in respect to the atmospheric pressure. This can be achieved by contracting
the muscles of inhalation, the diaphragm and external intercostal muscles between
the ribs [13]. Exhalation is mostly passive in normal stress and occurs by relaxing
of the respiratory muscles and elastic ﬁbers in the lungs.
Eﬃcient gas exchange in the alveoli requires a large airliquid interface, and the
total surface area of the approximately 500 million alveoli in the adult human lung
can be up to 80m2 [15,17]. The volume of an alveolus is ∼4.2× 106 µm3 (∼200 µm
in diameter) and its limited by a 0.4 µm thick respiratory membrane wall [17]. The
walls of the alveoli are composed of a single, thin layer of two types of alveolar
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epithelial cells (see Fig. 2.2) [12]. The thin type I alveolar cells make up 95% of the
wall and are the main site for gas transfer. The rest of the wall consists mostly of type
II alveolar cells [18]. Their important function is to produce and secrete a thin layer
of lipids and proteins called the pulmonary surfactant that covers the ﬂuid lining
inside the alveoli and prevents the lungs from collapsing at the end of expiration by
lowering the surface tension at the interface [2]. The alveoli also contain alveolar
macrophages that destroy pathogens that reach the respiratory zone, and participate
in the recycling of used pulmonary surfactant with type II alveolar cells [19].
Pulmonary surfactant
Figure 2.2 Gas exchange at the alveoli occurs through the respiratory epithelium. The
walls of the alveoli is covered by type I alveolar cells (95%) and type II alveolar cells (5%).
Type II cells secrete surface-active lung surfactant that covers the airliquid interface.
Alveolar macrophages participate in innate defense against pathogens and in the recycling
of the surfactant. Modiﬁed from [20].
To oxygenate the blood, O2 has to diﬀuse from the alveolar cavity through the
respiratory membrane, into the blood in the pulmonary capillaries that cover about
70% of the outer alveolar surface area, while CO2 mostly dissolved in the blood
diﬀuses into the opposite direction [12]. Dissolved CO2 is an essential part of blood,
and it is part of the carbonate buﬀer system that controls the pH of blood [21].
The gas exchange at the respiratory zone is driven by the diﬀerence in the partial
pressures of the gases in the alveolar air and the capillary blood [13]. As a non-
polar molecule, O2 has a low solubility in water. Without an eﬃcient O2 carrier
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in the blood, the transfer of dissolved oxygen from the alveoli to the blood could
not support the need of O2 for aerobic respiration [12,15]. Hemoglobin is a protein
in the oxygen carrying red blood cells involved in the process of O2 uptake in the
capillaries in alveoli, and O2 transport from the respiratory organs to the rest of the
body.
2.2 Pulmonary Surfactant
Pulmonary surfactant is a lipidprotein complex produced and secreted onto the res-
piratory surface by type II alveolar cells [22]. It covers the whole airliquid interface
of the alveoli, and some pulmonary surfactant can be found also in other parts of the
respiratory zone, which has been considered to be overﬂown from the alveoli [2,23].
The main function of the pulmonary surfactant is to reduce the surface tension of
alveoli from approximately 70mN/m measured at the interface of pure water and
air at physiological temperature, to close to 0mN/m in the compressed state of the
surfactant, thus preventing the alveoli from collapsing during exhalation [24]. With-
out the surfactant, the diﬀerence in the internal pressures between diﬀerent sizes
of interconnected air bubbles that are basically the alveoli would cause the collapse
of the smaller bubbles due to the air ﬂowing from the smaller bubbles with higher
internal pressures into the larger bubbles [14]. The surface tension of the pulmonary
surfactant at equilibrium, without compression is 25mN/m [24]. The surfactant
also lowers the force needed to be supplied by the diaphragm during inhalation [14],
and signiﬁcantly accelerates the diﬀusion of O2 through the airliquid interface at
the surface of the alveoli [4]. In addition to the essential biophysical advantages of
pulmonary surfactant, it also participates in innate defense mechanisms [25].
The pulmonary surfactant consists of about 90% of lipids and 10% of surfactant
associated proteins (SPs) by mass (see Fig. 2.4) [24, 26]. The surfactant is assem-
bled, stored, and secreted by type II alveolar cells in organelles called lamellar bodies
(LBs) in a form of tightly packed membrane structures (see Fig. 2.3) [2]. LBs are se-
creted across the type II alveolar cell wall via exocytosis to the alveolar hypophase
where they unravel and form tubular myelin (TM) and other smaller intermedi-
ate lipidprotein structures before associating with the monolayer at the airliquid
interface [2, 27]. TMs are not obligatory for the delivery and exchange of lipids
at the pulmonary surfactant and thus, LBs are believed to be the primary form of
lipid transport in the alveolar ﬂuid [22]. The monolayer is at the airwater interface,
connected to a network of membranes between the interfacial ﬁlm and other surface-
associated structures that act as reservoirs of surface active molecules [26, 28]. The
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surfactant abilities of the interfacial monolayer are a consequence of the amphipathic
nature of phospholipids.
Figure 2.3 Pulmonary surfactant structures in the alveoli. The pulmonary surfactant
is synthesized and packed into lamellar bodies (LB) in the type II alveolar cells (pneumo-
cytes), and secreted into the alveolar ﬂuid. The LBs unravel in the hypophase and form
multilamellar vesicles, tubular myelin (TM), and other bilayer structures. The adsorption
of phospholipids is mediated by the hydrophobic surfactant proteins SP-B and SP-C at the
airliquid interface, where the surfactant consisting of the phospholipids and the proteins
forms a surface active monolayer. The surfactant is recycled by alveolar macrophages and
type II alveolar cells. Modiﬁed from [20].
2.2.1 Lipids in the Pulmonary Surfactant
The pulmonary surfactant has a unique lipid composition compared to most mem-
branes in mammalian tissues (see Fig. 2.4) [19]. Diﬀerent lipids comprise approxi-
mately 90% of the pulmonary surfactant by mass and they are mainly responsible
for forming the surface active monolayer ﬁlms at the airliquid interface of the alve-
oli [19, 24, 26]. By mass the pulmonary surfactant consists of 80% of phospholipids
and about 10% of neutral lipids, most of which is cholesterol (CHOL) [2]. Zwitteri-
onic phosphaditylcholines (PCs) comprise ∼65% of pulmonary surfactant by mass,
over half of which is dipalmitoylphosphatidylcholine (DPPC, 16:0/16:0) [24]. An-
ionic phospholipids, like phosphatidylglycerol (PG) and phosphatidylinositol (PI)
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comprise ∼1015% of surfactant by mass [2]. Phosphatidylethanolamine (PE), sph-
ingomyelin (SM), and phosphatidylserine (PS) appear in minor amounts in extracted
pulmonary surfactant but they are considered to originate from other sources [19,29].
Structures of the most important pulmonary surfactant lipids are shown in Fig. 2.5.
40%
25%
15%
10%
6%
1%
1%
0.5%
1.5%
DPPC
Unsaturated PC
Anionic lipids, PG+PI
CHOL, other neutral lipids
SP-A
SP-B
SP-C
SP-D
Other proteins
Figure 2.4 Composition of pulmonary surfactant. By mass 90% of pulmonary surfactant
consists of lipids and 10% of surfactant proteins. DPPC is the most abundant phospholipid,
and it is mainly responsible for the surface active properties of the surfactant. Modiﬁed
from [1].
The amount of DPPC and PG lipids is unusually high in pulmonary surfactant
compared to other tissues [19]. Together with cholesterol these three lipid types are
responsible for most of the biophysical activity of the pulmonary surfactant [23].
The ratio of disaturated and unsaturated phospholipids has been observed to be
constant (∼1:1) among adult mammalian lung surfactants [19,23], DPPC being re-
sponsible for the disaturated phospholipid fraction in the pulmonary surfactant [2].
Anionic surfactant lipids like PG are important for the function and binding of the
hydrophobic surfactant proteins [24, 30], and cholesterol aﬀects the ﬂuidity of the
pulmonary surfactant at physiological temperatures [31]. Equal amount of satu-
rated and unsaturated lipids is required for the stability of surfactant layers at high
compression rates while at the same time having enough ﬂuidity and dynamics [29].
DPPC is considered to be the most important lipid in the surfactant as it is
essential for lowering the surface tension of the surfactant close to 0mN/m during
compression at physiological temperatures [32]. This low surface tension prevents
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the alveoli from collapsing. The disaturated acyl chains of DPPC can be packed
to a very high density at the airliquid interface, thus reducing the surface tension
required to stabilize the interface at the end of expiration [32]. DPPC has a main
transition temperature (Tm) of 41◦C in bilayers, which is higher than the physiolog-
ical temperature, thus pure DPPC membranes in the alveolar hypophase would not
be fully ﬂuid at the body temperature of 37◦C [33]. This would inevitably hinder
the spreading of surfactant throughout the compressionexpansion cycles [34]. The
unsaturated phospholipids and cholesterol lower the Tm of pulmonary surfactant
membranes below the values of pure DPPC membranes and make them ﬂuid at
physiological temperatures [31]. The most common unsaturated phospholipid and
the second most common PC in pulmonary surfactant is palmitoyloleoylphoshatidyl-
choline (POPC, 16:0/18:1), with Tm of −3◦C [35]. Most of the surfactant anionic
lipids are also unsaturated [20]. The unsaturated phospholipids lower the Tm of
the pulmonary surfactant and together with the saturated lipids, provide the struc-
tural scaﬀold for the connected membrane structures that make up the pulmonary
surfactant system [20].
Phosphatidylglycerol (POPG, 16:0/18:1) and other anionic phospholipids have
been suggested to be important for the proper function and binding of the two
hydrophobic pulmononary surfactant proteins (SP-B and SP-C) to surfactant mem-
branes and monolayers [24, 30]. Both SP-B and SP-C have positively charged
residues that could interact with the anionic lipids [3]. PG phospholipids are one
of the minimal components required for the construction of TM in the type II alve-
olar cells along with DPPC, SP-A, SP-B and Ca+ [26], which also implies speciﬁc
interaction between PG and SP-B. Electrostatic interactions with the hydrophobic
surfactant proteins would justify unusually high concentrations of anionic lipids (PG
and PI) in the pulmonary surfactant compared to other tissues [3]. POPG is also an
indicator of lung maturity in neonates, concentration of which can be tested from
the amniotic ﬂuid before delivery [19].
Cholesterol in general aﬀects the packing of lipid membranes and modulates their
thermodynamic properties, which can also be seen in pulmonary surfactant [1].
Two distinctive ﬂuid phases, liquid ordered (Lo) and liquid disordered (Ld) phase,
can be seen in native pulmonary surfactant preparations at physiological tempera-
tures [20, 31]. Without cholesterol and the hydrophobic surfactant proteins only a
solid and a ﬂuid phase would coexist [20]. The Lo and Ld phases have small dif-
ferences in their lipid composition. The Lo phase is enriched in DPPC and choles-
terol [36], which enhances the ﬂuidity of the Lo phase at physiological temperatures
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by decreasing the packing of the lipids by intercalating between the phospholipid
molecules [37]. Without cholesterol, the Lo phase would be in a more condensed
and ordered but less ﬂuidic gel (Lβ) phase below the Tm [38,39]. On the other hand,
the Ld phase transforms to more ordered Lo in the presence of cholesterol. The Ld
phase contains a higher proportion of unsaturated lipids, which makes it more ﬂuid
at lower temperatures compared to the Lo phase. By increasing the ﬂuidity of the
membrane, cholesterol also limits the minimum surface tension attainable during
compression of the ﬁlm [20].
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Figure 2.5 Structures of the main lipids in the pulmonary surfactant (a) DPPC, (b)
POPC, (c) POPG, and (d) cholesterol.
Once reaching the airliquid interface, the pulmonary surfactant organizes into
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ordered and/or disordered phases, the proportions of which depend on the lipid
composition, temperature, and compression state of the ﬁlm [29]. These domains
are analogous to the Lo and Ld phases in surfactant bilayers. The lipids arrange into
a liquid condensed (Lc) phase at low molecular areas at high surface pressures, and
into a liquid expanded (Le) phase at high molecular areas and low surface pressures.
Between these two there is a coexistence Lc/Le phase where domains of both phases
can be observed. When surface pressure is gradually applied to the ﬁlm during
compression, the Le phase transitions to the Lc/Le phase, and eventually a phase
transition from Lc/Le to Lc occurs [1]. If the surfactant is further compressed after
the limit of surface pressure has been exceeded, the monolayer collapses and a 2D to
3D transition of surfactant monolayers to membrane-associated disk-like structures
occurs (see Fig. 2.3) [40]. Cholesterol enhances the adsorption and respreading of
surfactant lipids from the collapsed phases to the monolayer [41].
The surfactant phospholipids are directly associated with the surface tension re-
duction of the pulmonary surfactant, however none of the phospholipids alone or in
conjunction with each other can maintain the function of the surfactant [3]. The
tight packing of DPPC upon compression is responsible for the most of the sur-
face tension reducing eﬀect of the surfactant [32, 42], but the rate of adsorption
of pure DPPC vesicles from the hypophase to the airliquid interface is extremely
slow [42, 43]. The unsaturated and anionic surfactant lipids support faster adsorp-
tion rates, but can not achieve low enough surface tension values without irreversible
collapse and squeeze-out of the lipids [44]. The presence of hydrophobic surfactant
proteins, discussed more in the next section, surpasses the shortcomings of surfac-
tants consisting of only phospholipids [3]. These proteins are involved in both surface
tension reduction and reversible phospholipid transfer at the pulmonary surfactant.
Moreover they accelerate the adsorption of the lipids almost to the maximum extent
possible [45,46].
2.2.2 Pulmonary Surfactant Proteins
Pulmonary surfactant contains 810% surfactant speciﬁc proteins by mass [26].
There are four major surfactant proteins, the hydrophilic SP-A and SP-D, and
the hydrophobic SP-B and SP-C [47]. All four surfactant proteins have been de-
tected also from the human tear ﬂuid, the ocular surface, and tissues of the lacrimal
apparatus [48, 49], where they might have similar functions as in the pulmonary
surfactant. This is not surprising as the alveoli and the eye are the only two sites
in the human body with an airwater interface. SP-A and SP-D belong to the col-
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lectin family of proteins and make up 56% and 0.5% of the surfactant by mass,
respectively [3]. Both hydrophilic SPs participate in innate defense mechanisms by
binding speciﬁc ligands on the surface of pathogens including bacteria, viruses, and
fungi [50]. SP-A is also associated with surfactant phospholipids and is needed for
the formation of TM in the pulmonary surfactant hypophase [51]. Regardless of
their functions in the pulmonary surfactant neither is essential for the surface active
functions of the surfactant and lack of these proteins does not cause any respiratory
dysfunction [26,52].
SP-B and SP-C are very hydrophobic and always associated with surfactant mem-
branes [53]. These proteins are essential for the proper surfactant activity as they
promote eﬃcient interfacial adsorption, ﬁlm stability, and re-spreading of the lipids
during the course of the breathing cycle [42, 54, 55]. Lack or deﬁciency of SP-B or
SP-C are common causes of diﬀerent severe respiratory pathologies [7, 56]. Proper
expression of SP-B is essential for the viability of a newborn and deﬁciencies in the
expression of the functional protein leads to lethal respiratory distress syndrome
shortly after birth [5759]. SP-C deﬁciency is associated with the development of
chronic lung disease in humans but the protein is not as critical for surfactant ac-
tivity and breathing as SP-B [60].
SP-C is a small 4.5 kDa and 35 residue transmembrane peptide. It has a primarily
α-helical secondary structure with an N-terminal with two palmitoylated cysteine
residues and a positive net charge of +3 e at pH 7. The C-terminal α-helix is
enriched in aliphatic residues [61,62]. The positive charge at the N-terminus causes a
preferential interaction with anionic surfactant lipids [63]. The palmitoylated chains
are required for the tight association of the N-terminus with bilayers and interfacial
ﬁlms, which prevents its exclusion from the surfactant interface during compression
expansion cycles [64]. SP-C functions by promoting and stabilizing membrane
membrane and membranemonolayer contacts [46, 65] and SP-C has been shown
to perturb lipid packing in membranes [66]. One of the most important functions
for the protein could thus be to promote lipid transfer between bilayers or between
bilayers and monolayers independently, or in conjunction with SP-B [55,65,67].
Hereafter this thesis will concentrate on the structure and function of the most
important surfactant protein SP-B, and further discussion on the other surfactant
proteins is thus omitted unless related to the function of SP-B.
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2.2.3 Structure and Function of Surfactant Protein B
Surfactant protein B belongs to the diverse lipid-interacting family of saposin like
proteins (SAPLIPs) [5]. The SAPLIP family contains over 200 proteins in organisms
ranging from the most primitive eukaryotes, like amoebozoans, to all mammals [68].
Thus, the SAPLIP family is assumed to have originated very early in the eukary-
otic life. SAPLIPs are very diverse in protein sequence, but they share a few key
features for the saposin fold: conserved hydrophobic amino acids in the core of the
protein, six strictly conserved cysteines that form three stabilizing intramolecular
disulphide bridges (see Fig. 2.6), and a high helical content of four or ﬁve α-helices
in common positions [68]. The human genome codes for a total of 11 proteins with
the SAPLIP fold in their structure. Three universal functions have been suggested
for the SAPLIPs: membrane binding with local disordering of the lipids, membrane
perturbation without permeabilization, and permeabilization by perturbation of the
lipids [68], the latter being an assumed function of oligomeric proteins.
SP-B is a 8.7 kDa and 79-residue polypeptide that contains a high proportion
of hydrophobic amino acids (approximately 52%) and adopts a mainly α-helical
(3045%) secondary structure [53,69,70]. SP-B contains the six conserved cysteines
of SAPLIPs, forming three intramolecular cysteine bridges at positions C8C77,
C11C71 and C35C46, and also a SP-B speciﬁc seventh cystein C48 that forms a
covalent homodimer of 19 kDa (see Fig. 2.6) [69,71]. SP-B is also the only SAPLIP
protein that is permanently membrane-associated due to its high hydrophobicity [5].
SP-B monomer has a positive net charge of +7 e, which leads to its observed pref-
erential interaction with anionic surfactant lipids, especially PG [63, 72, 73]. SP-B
has been shown to distribute preferentially into the disordered phase in bilayers and
interfacial ﬁlms [31,74].
SP-B is synthesized in the endoplasmic reticulum of the type II alveolar cells
as a 381-residue precursor peptide proSP-B [75]. This precursor is processed post-
translationally into the functional protein by proteolytic cleavage in at least three
distinctive steps before it is packed into the mature LBs shown in Fig. 2.3 [7678].
Dimerization and ﬁnal permanent lipid association of SP-B does not occur until
both ﬂanking propeptides are cleaved from the precursor in the last step of SP-B
processing in the intermediate composite bodies (CB), which are a precursor form
of the LBs [71,78]. Both ﬂanking regions of the precursor peptide contain functional
saposin-like structures, but these peptides have not been observed in the alveolar
ﬂuid [53,79].
Mutations in the SP-B precursor can interfere with the processing of both SP-B
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and SP-C, which indicates important proteolytic and chaperone functions of the
propeptides of SP-B [76]. One of the important functions of mature SP-B is to
mediate the packing of the surfactant lipids into LBs after the last step of post-
translational processing [58,80]. Defects in SP-B expression cause signiﬁcant reduc-
tions in the number and size of LBs secreted by type II alveolar cells [58,80]. Severe
mutations or lack of expression of SP-B leads to lethal RDS shortly after birth due
to the total lack of pulmonary surfactant at the airliquid interface [75, 81].
Two seemingly contradictory models for the orientation of membrane binding
for SP-B have been detected in experiments (see Fig. 2.7) [73]. The ﬁrst model
suggests a superﬁcial binding to the surface of bilayers and surfactant monolayers
with the amphipathic helical structures as well as the positively charged residues in
the C- and N-terminal regions of SP-B, causing little or no perturbations in the acyl
chains of surfactant phospholipids [67,83,84]. The second model suggests much more
signiﬁcant perturbations in acyl chain packing and order, and deeper penetration of
SP-B into lipid membranes [63,85,86].
The observed orientation and level of membrane penetration of SP-B is highly
dependent on the method used to prepare the samples and study the lipidprotein
interactions [43, 73, 87]. Samples prepared with the SP-B in the organic solvent 
isolated lipid fraction show deeper penetration of the protein inside bilayers whereas
addition of the protein to preformed phospholipid vesicles leads to more superﬁcial
binding [43,87]. These two levels of membrane binding could indicate diﬀerent func-
tional stages of the protein: a superﬁcial inactive membrane associated form, and a
functional, more deeply inserted form of SP-B [87]. Altogether more experimental
and molecular dynamics studies of the protein support a model of superﬁcial or in-
termediate binding where the N- and C-terminal regions of the protein play a crucial
functional role [73, 8890]. The importance of the role of the N- and C-termini is
further validated by the signiﬁcant activity of the termini-including SP-B fragment
called mini-B [91,92].
A possible model suggested for the interaction of SP-B with lipid membranes
includes both electrostatic interactions by the cationic residues mainly in the N- and
C-terminal and helical regions of the protein, and hydrophobic contacts by essential
membrane binding residues, such as W9 in the N-terminus [3, 93, 94]. Mutation
or oxidative modiﬁcation of W9 has been shown to aﬀect the surface activity and
membrane association of SP-B, which could be caused by the improper binding of
the protein to the surfactant membranes [93, 95]. The aromatic side chain of W9 is
believed to anchor SP-B ﬁrmly in the correct orientation to the surface of surfactant
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5. 10. 15. 20. 25. 30. 35. 40.
SP-B_h FPIPLPYCWLCRALIKRIQAMIPKG.....ALAVAVAQVCRVVPL
SP-B_b FPIPIPYCWLCRTLIKRIQAVIPKG.....VLAMTVAQVCHVVPL
SP-B_p FPIPLPFCWLCRTLIKRIQAVVPKG.....VLLKAVAQVCHVVPL
SAP_A ....SLPCDICKDVVTAAGDMLKDNATE.EEILVYLEKTCDWLPK
SAP_B ....GDVCQDCIQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGP
SAP_C ...SDVYCEVCEFLVKEVTKLIDNNKTE.KEILDAFDKMCSKLPK
SAP_D ...DGGFCEVCKKLVGYLDRNLEKNSTK.QEILAALEKGCSFLPD
45. 50. 55. 60. 65. 70. 75.
SP-B_h VA.GGICQCLAERYSVILLDTLLGRM.LPQLVCRLVLRCSM..
SP-B_b LV.GGICQCLVERYSVILLDTLLGRM.LPQLVCGLVLRCSS..
SP-B_p PV.GGICQCLAERYIVICLNMLLDRT.LPQLVCGLVLRCSS..
SAP_A PNMSASCKEIVDSYLPVILDIIKGEMSRPGEVCSALNLCESLQ
SAP_B GM.ADICKNYISQYSEIAIQMMMH.M.QPKEICALVGFCDE..
SAP_C SL.SEECQEVVDTYGSSILSILLEEV.SPELVCSMLHLCSG..
SAP_D PY.QKQCDQFVAEYEPVLIEILVEVM.DPSFVCLKIGACPSAH
(a) Sequence alignment
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(b) Primary structure of SP-B
Figure 2.6 (a) Sequence alignment of SP-B and other selected SAPLIPs using
CLUSTAL [82]. SP-B_h, SP-B_b, and SP-B_p are the human, bovine, and porcine
SP-B sequences, respectively, and SAP_A, SAP_B, SAP_C, and SAP_D are the four
human saposin proteins, from A to D, respectively. Numbering of residues based on the
human SP-B sequence. (b) A representation of some of the most important features of
the primary structure of SP-B, especially the intra-chain cysteine bonds (yellow), positive
residues (blue), negative residues (red), aromatic (green), and other conserved hydrophobic
residues (brown in the sequence alignment) important for membrane binding and protein
function.
phospholipid layers [96,97]. The positioning of these membrane interacting residues
in many of the proposed SAPLIP homology models for SP-B could imply a speciﬁc
orientation for the SP-B in surfactant membranes [5].
Functionally SP-B is indispensable for the three most important biophysical pro-
cesses needed for proper pulmonary surfactant behavior during normal compression
expansion breathing cycles. These include: very rapid adsorption of surfactant
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A B
Figure 2.7 Suggested orientations for the membrane binding of SP-B dimer. A: The ﬁrst
model, SP-B dimer exhibits a superﬁcial interaction with the membrane surface. B: The
second model, SP-B attains a transmembrane orientation or inserts deeper into one leaﬂet
of the membrane [73].
material from the aqueous hypophase into the airliquid interface, good compress-
ibility while still upholding the low surface tension and stability during expiration,
and very eﬃcient re-extension and spreading of the surfactant during inspiration [3].
These functions are all related to SP-B's ability to cause lipid acyl chain perturba-
tions [63, 85], lipid reordering and domain formation [98], pore formation [99, 100],
leakage of aqueous content from lipid vesicles [93,101], reduction of pulmonary sur-
factant surface tension [54], the exchange of lipids between surfactant layers and
reservoirs [42,93,102], and total fusion of lipid membrane structures [103,104], only
to name a few.
SP-B has been shown to mediate the interfacial adsorption and transfer of surface
active material from the aqueous hypophase into the surfactant to form the surface
active ﬁlm, alone and in conjunction with SP-C [55, 105]. SP-B is the main pro-
tein responsible for promoting surface activity and stability in the surfactant [105].
Together with SP-B, SP-C was observed to accelerate the eﬀect of initial surface
ﬁlm formation and re-extension after compressionexpansion cycles compared to
only SP-B in lipid extracts, which could indicate a synergetic eﬀect of the two hy-
drophobic surfactant proteins in the lipid exchange between surfactant layers and
reservoirs [105]. Both hydrophobic surfactant proteins have been observed to be
present at the surface of the LBs that are responsible for the transport of lipids to
the airliquid interface [55]. The adsorption and spreading of lipids from the LBs
to the interface is prevented in the presence of SP-B inhibitors. Thus SP-B func-
tions as a gate for lipid transfer during adsorption to the airliquid interface [55].
A conformational change of SP-B from an inactive closed to an active open form is
believed to occur when the protein reaches the airliquid interface, which could be
related to the depth of insertion of the protein into membranes at diﬀerent active
states [6, 55].
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The addition of SP-B into surfactant lipid extract improves the surface activity,
and higher surface pressures without collapse can be achieved compared to pure lipid
fraction [32,105]. The presence of SP-B is needed for the proper compressibility and
low surface tension of the pulmonary surfactant during compressionexpansion cy-
cles [32]. SP-B disrupts the Lc lipid microdomains in the coexistence Lc/Le phase
and creates a wider plateau range in surface pressure area isotherms (Π−A) i.e. it
creates more disorder in the surfactant while optimizing the behavior in the physi-
ological surface pressure range [42,106]. Higher surface pressures cause a reversible
2D3D structural transition in the surfactant in which part of the monolayer is
squeezed out of the surface [3, 105]. SP-B has been suggested to contribute to the
stabilization of this transition during both compression and expansion phases of
the cycle and thus contribute also to the eﬃcient re-extension and spreading of the
surfactant during inhalation [3, 105].
The traditional model for O2 permeation in lipid membranes, and especially in the
respiratory epithelium, assumes that the concentration gradient over the membrane,
or between the alveoli and the capillaries is the driving force for gas transfer [12].
As a small molecule O2 has been assumed to diﬀuse freely over the phospholipid
membrane based on the higher permeability compared to pure water surfaces [107,
108]. On the other hand, other studies have shown that pure lipid monolayers and
surfactant lipid extracts, although signiﬁcantly accelerating O2 diﬀusion at the air
liquid interface, are not alone enough to maintain high-rate oxygen transfer [4,109].
The permeation of O2 has been found to be three to four orders of magnitude lower
than expected by the traditional model, and thus the phospholipid membrane has
been considered a barrier to free O2 diﬀusion [109]. Based on their results with
O2 diﬀusion through phospholipid membranes, Ivanov et al. [109] suggested that
protein-mediated O2channels through the membranes of aerobic organisms could
be needed to further improve the ﬂow of O2.
The hydrophobic surfactant proteins in the pulmonary surfactant improve the
rate of O2 diﬀusion compared to a water interface, pure DPPC membranes, or sur-
factant extracts devoid of SP-B and SP-C [4]. The pulmonary surfactant is necessary
for its surface tension lowering function in the airliquid interface, but it could be
also closely related to the high transfer rate of O2 in the lungs. SP-B and SP-C pro-
mote connections and lipid transfer between the surfactant and the interconnected
bilayer structures below the surface [3, 22]. Oxygen partitions preferably into the
hydrophobic core region of the phospholipids [110]. The molecular connection of the
surfactant lipid structures mediated by SP-B and SP-C could allow O2 to partition
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into the tail region and diﬀuse rapidly through the alveolar hypophase using the
connected membrane structures as a scaﬀolding (see Fig. 2.8) [4].
air
liquid phase
Figure 2.8 Main functions of SP-B in pulmonary surfactant during breathing. SP-B
facilitates surfactant adsorption (solid red arrow on the right) and lipid spreading at the
airliquid interface, it preserves functional surfactant by maintaining low surface tensions,
and mediates lipid transfer between the surfactant monolayer and the connected bilayer
structures during compressionexpansion cycles. Interconnected lipid structures below
the surfactant could be associated with improved oxygen permeation needed for eﬃcient
breathing (left pathway marked with dashed arrows) compared to oxygen diﬀusion through
the hypophase (right pathway). Modiﬁed from [4] and [3].
Despite the essential role of SP-B in the biophysical activity of the pulmonary
surfactant system, a structural model and a molecular mechanism for the protein
have been lacking. Determination of the 3D-structure of SP-B has been experi-
mentally limited by its small size, the diﬃculty of extraction due to the extreme
hydrophobicity, and the lack of methods to produce recombinant version of SP-
B [5, 111]. Thus most protein models used in molecular dynamics studies so far
have been based on sequence alignment and homology modeling of the SP-B and
other SAPLIPs [112, 113]. There exist higher resolution models for the N- and
C-terminal amphipathic α-helical sections of SP-B, which are the basis for a func-
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tional 34-residue SP-B fragment called mini-B [11]. Mini-B contains two of the four
intramolecular disulﬁde bonds but lacks the C48 residue needed for covalent dimer-
ization. Mini-B has the same net charge of +7 e as native SP-B, and has been shown
to retain most of the activity of native SP-B [92].
SP-B extracted and puriﬁed in organic solvents from animal lungs has been ob-
served to exist as a covalently bound homodimer [114]. The dimerization occurs
at the last step of post-translational modiﬁcation, and has been suggested to be
related to its permanent membrane association in agreement with other oligomer-
izing SAPLIPs [5]. SP-B has been shown to have a strong tendency to form larger
non-covalent oligomers of dimers depending on the animal source, the puriﬁcation
method, solvents used, and the protein-to-lipid ratio. SP-B trimers have been found
in studies with bovine and ovine lung extracts [70, 101, 115], but higher oligomers
of up to octamers have been found with better puriﬁcation techniques and anal-
ysis methods [116]. SP-B has a tendency to form oligomers even in the absence
of C48-dependent intermolecular disulﬁde bonds [117]. This could be due to the
E51R52' and R52E51' ion pairs that are believed to further stabilize the disulﬁde
in the native state.
A recent study showed a signiﬁcant improvement in the quality of the suggested
structural model for SP-B [6]. The group was able to purify porcine SP-B using
detergent-solubilized pulmonary surfactant, and visualize large ring-like oligomeric
SP-B structures. Two homology models for non-covalent SP-B dimers were built
based on analogous structural variants of the human saposin B protein. These so-
called open and closed conformations for the SP-B dimers were further used to con-
struct larger oligomeric structures by optimizing the C48C48' as well as E51R52'
and R52E51' bond lengths between the dimers in docking calculations and subse-
quent ranking of the models. This resulted in two highest ranking structures for
a pentamer of dimers and a hexamer of dimers (see Fig. 2.9). These novel struc-
tural models have been used as a basis for the SP-B models built for this study, as
described in section 5.
2.3 Diseases Related to SP-B
According to World Health Organization (WHO) [9,118], every year approximately
15 million (over 10%) babies are born prematurely (before week 38 of gestation)
worldwide, and the number is rising. Over 1 million children die annually because
of complications caused by preterm birth [9]. Premature birth is a global problem,
but it is more common in low-income countries, in which the mortality of babies born
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Figure 2.9 A model for the 3D structure of the closed (left) and open (right) conformation
of the SP-B dimers, and in the middle closed (left) and open (right) conformation of the
SP-B hexamer of dimers. The ﬁgures below represent the experimentally obtained front
views of the 3D models built from negative stained oligomeric SP-B complexes [6].
before week 32 of gestation is over 50% due to the lack of feasible and cost-eﬀective
basic care for infections and breathing diﬃculties [118]. In addition to neonatal
mortality, complications caused by breathing diﬃculties with preterm children can
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result in lifelong disabilities, including learning disabilities and visual and hearing
problems [9, 119].
The formation of the gas-exchange interface and the maturation of the lung is
controlled by a number of genes during the stages of sacculation (before birth) and
alveolarization (after birth) [120,121]. The most important steps in the pulmonary
maturation happen at the end of gestation before week 35 [121], thus majority of
preterm babies born below 32 weeks of gestation develop the condition of respira-
tory distress syndrome (RDS) [121]. RDS is caused by lung immaturity and the
deﬁciency of surfactant lipids in the lungs, and the condition is fatal without correct
treatment [1,81,121]. RDS can be treated by administration of a clinical surfactant,
in a treatment called surfactant replacement therapy (SRT) [29]. The replacement
surfactant reduces the surface tension in the lungs and prevents the immature alve-
oli from collapsing [122]. Preterm babies of only 25 weeks of gestation can survive
with SRT [122], but the treatment is still unattainable in low-income countries due
to its high cost [9].
Both synthetic and natural pulmonary surfactants are eﬀective in treating RDS,
but the function of therapeutic surfactants has been shown to be highly dependent on
SP-B content, or the content of SP-B and SP-C analogues [81,123]. Synthetic SP-B
analogs, such as mini-B [11,92,124], are used in replacement surfactants, but they are
not as eﬀective as natural SP-B [124]. Mini-B consist of N- and C-terminal fragments
of SP-B covalently bound together [11]. The production of functional recombinant
SP-B has not been successful [29]. Understanding the molecular mechanism behind
the function of SP-B can help in the development of an aﬀordable and eﬀective
synthetic replacement surfactant that could save hundreds of thousands of prenates
annually in low-income countries by lowering the price of SRT.
Mutations in the gene encoding for SP-B, SFTPB, are often fatal in neonates [29,
120, 121] without lung transplantation [81, 120]. The 381 amino acid preproprotein
encoded by this gene is expressed and processed to the functional 79 amino acid
protein in type II epithelial cells [120]. The SP-B preproprotein is associated with
the proteolytic processing of the two hydrophobic surfactant proteins [58,120]. Mu-
tations in SFTPB gene interrupt the post-translational modiﬁcation of SP-B and
SP-C, which leads to the accumulation of partially processed, inactive forms of SP-
B and SP-C in the alveoli [120, 121]. Neonates with mutated SP-B show similar
symptoms to RDS, but SRT is not suﬃcient in the treatment of the condition [29].
Less severe mutations in SFTPB are associated with chronic lung diseases, similar
to those caused by defects in SP-C expression [29,125].
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3. MOLECULAR DYNAMICS
In this thesis novel dimer and oligomer structures of SP-B, their interactions with
lipid monolayers and bilayers, and their possible role in oxygen transfer at the air
liquid interface of lung alveoli are studied using classical molecular dynamics (MD)
simulations. All simulations were performed using the GROMACS simulation pack-
age [126128]. This chapter provides a short overview of MD simulations, based on
the user manual of GROMACS [129], as well as Refs. [130132].
Molecular modeling and simulation, especially that of large biological polymers
such as proteins, lipids, and nucleic acids, have been rapidly growing multidisci-
plinary ﬁelds that have brought together scientists from a multitude of engineering
and natural science ﬁelds. Biologists, chemists, and physicists are needed to de-
scribe the system of interest at an appropriate level, from the cellular level of the
system down to the electronic level as well as the underlying forces behind the inter-
action between separate atoms. Mathematicians, computer scientists, and engineers
are needed to formulate and reﬁne algorithms and numerical models for the MD
software and to eﬃciently implement them to a variety of diﬀerent computational
platforms, from a simple desktop computer to a state-of-the-art supercomputer.
The study of single biological molecules like proteins and lipids has been restricted
by the size and timescale limitations of modern in vitro experimental methods.
Often in the study of biomolecules, suitable experiments can be close to impossible
to perform due to the nanometer size of the systems of interest and the nanosecond
timescales of the reactions and interactions. MD simulations are a useful method in
conjunction with experiments to explain the results at a molecular level and to build
new models of biological systems. Simulations are often cheaper than experiments
and they can be used to test many diﬀerent sets of experimental conditions before
actual laboratory experiments are conducted. Results from MD can thus be used to
plan the tests and focus the limited experimental resources more eﬃciently.
Computational models are always highly-simpliﬁed versions of real systems and
reactions that occur in reality. The goal of biomolecular modeling and MD is to
describe a complex system or reaction occurring in nature with as realistic as pos-
sible atomistic or coarse-grained (CG) models that can be used to understand and
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predict macroscopic properties of the system [129]. Classical MD simulations used
in this thesis can be used to study systems governed by molecular mechanics (MM),
or in other words systems that can be studied by using Newton's laws of motion and
disregarding possible chemical reactions that might occur. Classical MD does not
take into account quantum mechanics (QM), which includes e.g. chemical trans-
formations governed by strong forces, such as chemical reactions, enzyme catalysis
and photochemical reactions. The exclusion of QM in classical MD simpliﬁes the
computational process so that much larger systems and longer time scales can be
achieved compared to computational quantum mechanics or the combination of QM
and classical MD in mixed QM/MM simulations [130]. In QM/MM simulations
part of the system can be treated by taking into account quantum mechanics, while
majority of the system is treated as an atomistic MM simulation.
A schematic of the general algorithm for MD simulations is given in Fig. 3.1. MD
simulation always starts with the preparation of the system of N particles, relaxation
of the system by minimizing the initial forces aﬀecting the system, equilibration
simulations with possible restrains on some molecules, until the system is ﬁnally
ready for actual production simulations.
3.1 Initial Conditions
The initial conditions of an MD simulation system are comprised of the simulation
box size, the number, position, and starting velocities of all the particles in the sys-
tem, their chemical identity, and the possible bonds each particle shares with others.
Selecting the initial condition should be done with proper care, as the starting con-
ﬁguration often determines the success or the failure of a simulation. The goal is to
build a simulation system that models the properties of a real physical system as re-
alistically as the method enables. The system needs to be deﬁned and its boundaries
set so that only relevant features are studied. This might require simpliﬁcations in
the system by e.g coarse-graining or by otherwise omitting unnecessary precision
and limiting the size of the system.
Starting velocities of all particles in the system are required after the relevant
macromolecules (proteins, lipids, carbohydrates, nucleic acids) and solvent are placed
in a simulation box. The shape and size of the simplest cubic simulation box is de-
ﬁned by three basis vectors of the periodic box. Other shapes of the box exist with
diﬀerent number of basis vectors. In some applications the proper selection of the
simulation box shape can accelerate the simulation as less solvent is required to ﬁll
the smaller volume. If the initial velocities of the atoms at the beginning of a sim-
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Figure 3.1 A general MD algorithm.
ulation are not known, they can be set by the user or they can be generated from
the MaxwellBoltzmann distribution at a given absolute temperature T :
p(vi) =
√
mi
pikBT
× exp
(
−miv
2
i
2kBT
)
, (3.1)
where p is the probability density as a function of particle velocity vi, mi is the
mass of the particle, kB is the Boltzmann's constant, and T is the temperature. A
schematic picture of the velocity distribution generated for particles of three diﬀerent
masses is shown in Fig. 3.2.
MD simulations require a molecular description of the particles to be simulated,
which is generally called a topology. The topology of the system contains parameters
that describe the physical properties of all the particles and their interactions with
each other. The properties of individual particles contain information of their atom
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Figure 3.2 Maxwell-Boltzmann velocity distribution calculated at a physiological tem-
perature of 310 K for three diﬀerent particle masses representing hydrogen (1 u), carbon
(12 u), and oxygen (16 u).
type, mass, and charge, while the inter-particle relations contain the bonds, angles
and dihedrals between atoms. One must note that in classical MD simulations the
topology is a ﬁxed list where all of the bonded and special interactions are deﬁned
at the beginning of the simulation and they are not changed during the course of
the simulation run. Thus, covalent bonds can not typically be formed or broken
in classical MD simulations, and no chemical reactions can occur. In biological
applications of MD, one has to consider the protonation state of a protein at a
relevant pH as it remains constant during the simulation.
The initial coordinates of atoms in a structure can be attained from an experimen-
tal crystal structure, or if that is not available, then from otherwise built theoretical
models, or the combination of both. These coordinates do not often represent the
minimum potential energy attainable by the system. The total potential energy
of the system needs to be minimized before simulation to prevent the system from
collapsing or exploding due to the large forces caused by clashing atoms. Energy
minimization relaxes the possible tensions or atomic clashes and prepares the simula-
tion system for equilibration simulations. Thermodynamic and structural properties
of the simulation system are monitored in the minimization and equilibration steps
until stability of the system is achieved. This can require a varying amount of simu-
lation time and precision, but these procedures are necessary to prevent any unusual
behavior in the production phase.
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3.2 Force Fields
The force ﬁeld is the description of the interactions between atoms or coarse-grained
particles in the simulation system as a set of potential functions and their associated
parameters. Force ﬁelds are used to calculate the forces acting on the atoms at each
step during the simulation. Equation 3.2 gives the total classical potential function
which is a combination of the bonded and non-bonded interactions. The bonded
terms include interactions of atoms linked by covalent bonds, and the non-bonded
terms include electrostatic and van der Waals forces:
VTOT = Vbonded + Vnon-bonded. (3.2)
The functional forms of the potential and the way the empirical parameters used
in the force ﬁeld are deﬁned diﬀer between force ﬁelds. Each force ﬁeld has its own
strengths and weaknesses so the user has to have some experience and judgment
when choosing the best ﬁtting force ﬁelds [133]. Due to their suitability for diﬀerent
types of simulation setups, the choice of a force ﬁeld has to be taken into account
also when analyzing and interpreting the results.
The force ﬁeld determines the level of detail and the time and length scales achiev-
able with current computational methods. Most common force ﬁelds used with the
GROMACS simulation package contain terms and parameters of either all atoms
(AA) in the system or ones that include united atom (UA) groups for carbon atoms
bonded with non-polar hydrogens. UA models oﬀer faster computation compared to
AA, but lack some accuracy that might be desired from an AA simulation. If even
more detail with smaller systems and shorter time scales are desired, a QM/MM
or QM force ﬁeld can be used. QM simulations are useful in creating and reﬁn-
ing parameters for AA force ﬁelds when combined with empirical data. Reactive
force ﬁelds, such as ReaxFF [134,135], can be used for simpler chemical reactions of
hydrocarbons, in which bonds can break and form during the simulation. Neverthe-
less QM/MM simulations of biomolecular systems require excessive computational
capacity to be implemented in large scale with modern technology.
Common AA and UA force ﬁelds used with GROMACS include e.g. OPLS/AA
[136], AMBER [137, 138], CHARMM [139, 140], and GROMOS [141, 142]. The
most universal force ﬁeld considering current state of parameters for all types of
biomolecules has been CHARMM [131], but the others have also been actively
developed to include parameters for e.g. nucleic acids, carbohydrates, and drug
molecules [139,143].
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MARTINI Coarse-grained models provide longer time and length scales at the
expense of molecular detail achieved with AA and UA force ﬁelds by reducing the
number of degrees of freedom in the system and allowing larger interaction time
steps. In these CG models the system is divided into simpliﬁed beads that represent
diﬀerent sets of atoms or functional groups and the interaction parameters are then
averaged over the grouped atoms. These so called eﬀective potentials are chosen so
that they reproduce the average interactions of the more detailed system. There has
been signiﬁcant development in the accuracy and eﬃciency of CG models in recent
years, and the parameters have been extended from lipids and proteins to include also
compounds such as carbohydrates, glycolipids, nucleic acids, and nanoparticles [144].
CG models are a useful method to probe a large number of diﬀerent simulation
setups when the molecular mechanism of function is yet unknown. For example
when the level of detail of the protein model of interest is not reliable due to the
assumptions and uncertainties in the modeling phase, or there is no previous model
for the function of the protein, many diﬀerent types of simulation system setups
can be tested. The validity of many diﬀerent conformational states of the same
protein can be evaluated eﬃciently. It is possible to move between atomistic and
CG levels of detail using methods such as protein coarse-graining [145], CG lipid
membrane building [146], and reverse coarse-graining of CG systems [147]. These
methods also provide a computationally eﬃcient method to build and equilibrate
complex membrane and membraneprotein structures before backmapping (ﬁne-
graining) them to AA detail.
One of the most used CG force ﬁelds is the MARTINI model also used in this
study [145,148150]. MARTINI has been used successfully to simulate a wide range
of biomolecular systems and it has been extended to include parameters for most
biologically relevant molecules [151153]. Compared to atomistic models, the MAR-
TINI force ﬁeld enables two orders of magnitude larger system sizes or longer sim-
ulations to be done while still maintaining enough chemical speciﬁcity for many
applications.
The MARTINI model is based on a four-to-one mapping method meaning that
on average four heavy atoms and associated hydrogens are represented by a single
interaction center. To simplify the model, there are only four types of interaction
centers: polar (P), non-polar (N), apolar (C), and charged (Q). Each particle type
is further divided into a number of subtypes based on their hydrogen-bonding ca-
pabilities or the degree of polarity, giving a total of 18 basic particle types [154].
Ring-like structures are mapped with a higher resolution of up to two heavy atoms
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and associated hydrogens per MARTINI particle because the four-to-one mapping
has been observed to be too coarse for ring geometry and behavior of molecules such
as cholesterol [149]. Thus also the size of the ring type beads is smaller compared
to the normal corresponding bead type. For computational eﬃciency the mass of
the CG beads is set to 72 amu (4 water molecules) for all beads, except for the
smaller beads in ring structures with a mass of 45 amu. One MARTINI water bead
corresponds to four atomistic waters, but each ion is represented by a single CG
bead that includes the ion and its ﬁrst hydration shell [154].
The MARTINI force ﬁeld's bonded and non-bonded interactions have been pa-
rameterized in a systematic way. The bonded parameters are derived from reference
atomistic simulations, while the non-bonded parameters are based on the repro-
duction of experimental partitioning free energies between polar and apolar phases,
mostly water and a hydrocarbon, for a large number of chemical compounds [154].
The MARTINI model aims for a broad range of applications without the need to
reparameterize the model each time for a diﬀerent system [144].
3.2.1 Bonded Interactions
Bonded interactions involve atoms or particles connected by chemical bonds within
a molecule. They include 2-, 3- and 4-body interactions. The three types of inter-
actions are shown in Fig. 3.3, and include the 2-body bond stretching, the 3-body
bond angle bending, and the 4-body dihedral angle torsional terms.
rij
i j
θijk
i
j
k φijkli
j k
l
Figure 3.3 Schematic representation of the three bonded interactions: bond stretching,
angle bending, and torsional terms
The total potential energy function of the bonded interactions can be written as
a sum of the three aforementioned factors as:
Vbonded = Vbonds + Vangles + Vdihedrals (3.3)
For example in the MARTINI force ﬁeld the bond stretching term between two
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covalently bonded atoms i and j (see Fig. 3.3) is represented by a harmonic potential
modeled after Hooke's law as:
Vbonds =
1
2
kbij (rij − bij)2 , (3.4)
where kbij is the force constant of the bond, rij is the distance between the particles,
and bij is the reference bond length value [149]. The bond-angle vibration between
a triplet of atoms ijk can also be represented by a harmonic potential on the angle
θijk as:
Vangles =
1
2
kθijk
(
θijk − θ0ijk
)2
, (3.5)
where kθijk is the angular force constant, θijk is the angle between the three par-
ticles, and θ0ijk is the reference angle. For aliphatic chains, cis double bonds,
and transunsaturated bonds the force constants and equilibrium bonds angles are
kθijk=25 kJ mol
−1 and θ0ijk= 180
◦, kθijk=45 kJ mol
−1 and θ0ijk= 120
◦, and
kθijk=45 kJ mol
−1 and θ0ijk= 180
◦, respectively.
The 4-body dihedral potential function can be divided again into the proper and
the improper dihedral terms. The dihedral terms describe the torsional angle be-
tween the two planes formed by four successive bonded particles. The total dihedral
potential function can be written as:
Vdihedrals = Vproper + Vimproper (3.6)
Proper dihedrals describe rotation of the ijk and jkl planes around the jk-axis
shown in Fig. 3.3. In GROMACS proper dihedrals are deﬁned according to the
IUPAC/IUB convention, where φ is the angle between the ijk and the jkl planes,
where 0◦ corresponds to the cis conﬁguration and 180◦ to the trans conﬁguration
accordingly. There are two diﬀerent potential functions used for proper dihedrals:
periodic and RyckaertBellemans potential. The former is used in the parametriza-
tion of the MARTINI force ﬁeld and can be written as:
Vproper,periodic = kφ (1 + cos (nφ− φs)) , (3.7)
where kφ is a force constant, n is a constant, φ is the torsion angle, and φs is
the reference torsion angle. The RyckaertBellemans potential function for proper
dihedrals can be written as:
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Vproper,RB =
5∑
n=0
Cn (cos (φ− 180◦)) , (3.8)
where Cn are constants for RyckaertBellemans potential deﬁned in the force ﬁeld,
and φ is the torsion angle.
Improper dihedrals are used to force planar groups remain planar and to prevent
changes in the chirality of a molecule. The simplest improper dihedral potential is
a harmonic potential deﬁned as:
Vimproper =
1
2
kξ
(
ξijkl − ξ0ijkl
)2
, (3.9)
where kξ is a force constant, ξijkl is the improper dihedral angle, and ξ0ijkl is the
reference angle value deﬁned in the force ﬁeld.
3.2.2 Non-bonded Interactions
Non-bonded interactions contain the interactions of particles that are not covalently
bonded but remain within a cut-oﬀ distance deﬁned in the force ﬁeld for van der
Waals and electrostatic interactions. The cut-oﬀ distance can be implemented to
speed up calculations, but especially in AA simulations the electrostatic interac-
tions are calculated eﬃciently with the Particle mesh Ewald-method (PME) [155],
which takes into account all interactions, also beyond the cut-oﬀ. Van der Waals
interactions involve short-range repulsion and long-range attraction terms between a
pair of particles. The non-bonded potential function is thus divided into two poten-
tial function terms, the Lennard-Jones (LJ) interaction describes the van der Waals
dispersion and steric repulsion terms and the Coulomb (C) term the electrostatic
interaction. The non-bonded interactions can be calculated as:
Vnon-bonded = VLJ + VC (3.10)
The non-bonded interactions are computed for each particle on the basis of a
neighbor list, which keeps eﬃciently track of the particles that are within the cut-
oﬀ radius. The LJ interactions contain the repulsion and dispersion terms and is
deﬁned as:
VLJ = Vrepulsion + Vattraction =
C
(12)
ij
r12ij
− C
(6)
ij
r6ij
, (3.11)
where C(12)ij and C
(6)
ij are constants depending on the pairs of particle types i and j,
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and the rij term is their relative distance respectively. The electrostatic interaction
between two charged particles can be calculated as a classical Coulombic potential
as:
VC =
1
4piε0
qiqj
εrrij
, (3.12)
where ε0 is the permittivity of vacuum, εr is the relative permittivity, qi and qj are
the charges of the particles, and rij is the distance between the two particles.
Special potential functions such as absolute or relative position restrains can
be applied to the simulation. The MARTINI model utilizes such relative position
restrains by creating a network of pseudo-bonds between non-bonded particles in a
protein structure. Due to the hereditary weaknesses of MARTINI to handle changes
in the secondary structure of proteins as well as the overemphasized forces in protein
protein interactions, an elastic network of harmonic bonds can be used to stabilize
and constrain a protein structure closer to its observed native state [154]. The
standard MARTINI model has a built-in option to add such harmonic bonds between
protein backbone beads to the topology based on a predeﬁned cut-oﬀ distance. The
behavior of a protein needs to be validated based on atomistic simulations and the
cut-oﬀ and the force constants chosen accordingly. One way is to use an optimized
method for combining an elastic network to a CG system, called ElNeDyn [156].
3.3 Equations of Motion
The standard MD sampling algorithm is a numerical solution of the classical New-
tonian equations of motion based on the interactions deﬁned in the force ﬁeld. To
compute the trajectory i.e. the evolution of positions and velocities of the N par-
ticles in the system, the forces acting on each particle at each time step have to be
evaluated. The force Fi acting on a particle is the negative gradient of the total
sum of the potential functions V (r1, r2, ..., rN) as:
Fi = −∂Vi
∂ri
(3.13)
where ri is the position of the particle i. The motion of the particles can be calculated
based on the forces acting on them as:
Fi = mi
d2ri
dt2
(3.14)
where mi is the mass of the particle i, and t is time.
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These two equations are solved simultaneously during each time step of the sim-
ulation. Several diﬀerent numerical MD integrators can be used in GROMACS to
calculate the new coordinates and velocities [157]. The two most commonly used
are the leap-frog integrator, which also the default MD integrator, and the Verlet
integrator. In the leap-frog algorithm the positions and velocities are calculated as:
ri (t+ ∆t) = ri(t) + vi
(
t+
∆t
2
)
∆t (3.15)
vi
(
t+
∆t
2
)
= vi
(
t− ∆t
2
)
+
Fi(t)
2mi
∆t (3.16)
where ri and vi are the position and the velocity vectors of the particle i respectively,
t is the point in time at which the system is studied at, ∆t is the time step used
in the simulation, and mi is the mass of the particle. At representative predeﬁned
intervals these data are saved in an output trajectory ﬁle.
3.4 Temperature and Pressure Coupling
Without a speciﬁed temperature and pressure coupling scheme, MD simulations
are performed in constant number (N), constant volume (V ), and constant energy
(E) environment, i.e. microcanonical ensemble (NVE). However, real experiments
on biological systems take place at a constant temperature (T ) and pressure (p)
(NPT), also called the isothermalisobaric ensemble, or constant temperature and
volume (NVT) conditions, also called the canonical ensemble. These conditions are
thus also desired in MD simulations, and achieved by selecting a suitable thermostat
for the temperature and a barostat for the pressure.
One of the most commonly used temperature coupling methods is the Berend-
sen weak coupling algorithm [158]. Also the NoséHoover thermostat [159, 160]
and the velocity-rescaling scheme [161] are often utilized in MD simulations with
GROMACS. The purpose of these algorithms is to slowly correct the deviations
in the temperature of the system. In the Berendsen coupling the deviations decay
exponentially with a time constant τ as:
dT
dt
=
T0 − T
τt
, (3.17)
where T0 is the reference temperature, and T is the temperature of the simulation
system. The other temperature coupling method utilized in this study is the velocity-
rescaling thermostat, which diﬀers from the Berendsen by an additional stochastic
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term to correct the kinetic energy distribution
dK = (K0 −K) dt
τT
+ 2
√
KK0
Nf
dW√
τT
, (3.18)
where K is the kinetic energy, Nf is the number of degrees of freedom, and dW a
Wiener process. All the particle velocities are corrected by a properly chosen random
factor. Velocity-rescaling produces a correct canonical ensemble while preserving the
advantages of the Berendsen thermostat [161].
NPT simulation conditions can be achieved with a pressure coupling algorithm
similar to the ones used in temperature coupling. The Berendsen pressure cou-
pling [158] rescales the simulation box vectors and the coordinates of the particles
to maintain the reference pressure P0 as
dP
dt
=
P0 − P
τp
, (3.19)
A scaling matrix µ given as
µij = δij − nPC∆t
3τp
βij{P0ij −Pij(t)}, (3.20)
is used in the method, where δij is Kronecker delta (0 if i 6= j, 1 if i = j ), nPC
the number of steps between pressure rescaling, τp the pressure time constant, β
the isothermal compressibility of the system, and P0ij the target pressure. The
Berendsen barostat is useful especially in the system equilibration phase if other
methods, such as the ParrinelloRahman, would produce unwanted oscillations of
the system.
The ParrinelloRahman pressure coupling [162,163] is used when accurate calcu-
lations on the thermodynamic properties of the system are of interest. It is similar to
the NoséHoover temperature coupling, and in theory gives the true NPT ensemble.
The barostat is calculated as:
db2
dt2
= VW−1b
′−1(P−Pref), (3.21)
where b is a matrix representing the box vectors, V is the volume of the simulation
box, W is a matrix parameter that determines the strength of the coupling and how
the box can be deformed, and the matrices P and Pref are the current and reference
pressures, respectively.
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3.5 Periodic Boundary Conditions
The simulation box is of ﬁnite size that depends on the ﬂuctuations caused by the
barostat. Hence without periodic boundary conditions (PBCs) this would mean that
at the edge of the box the system would end at a wall or a vacuum. However, in
MD simulations the simulation box is commonly made inﬁnite by imposing uniform
periodic images in all dimensions around the simulation box. Thus in reality there
are no boundaries and a particle that passes through one side of the box re-enters
in from the opposite side at the same time. The idea of PBCs is illustrated in Fig.
3.4.
Figure 3.4 Periodic boundary conditions
PBCs minimize the edge eﬀects of a ﬁnite system and the artifacts caused by
unwanted system boundaries, but also creates a potential new artifact of periodic
conditions. If the chosen simulation box size is too small, a particle can experience
the forces caused by other particles more than once. Similarly a large biological
macromolecule can experience forces caused by its own periodic image. Thus the
size of the simulation box needs to be deﬁned large enough to overcome these pos-
sible periodic artifacts from long-range interactions. The PBCs are combined in
GROMACS with the minimum image convention, so that only one, the nearest
image of each particle is considered for short-range non-bonded interaction terms.
3.6 Limitations of MD simulations
MD simulations are relatively simple in nature and rely on a well understood concept
like classical mechanics. Still, the user should be aware of the limitations of MD
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simulations and always check and validate their accuracy by comparing the behavior
of the model to experimental results. As described earlier, the MD method is based
on many approximations and assumptions that need to be taken into account when
preparing and simulating a new system.
The use of only classical mechanics in describing the motion of atoms is suitable
for most atoms in normal temperatures, but there are exceptions. For example, the
motions of lightweight atoms like hydrogen and helium, and the vibrations of oscil-
lating bonds can not always be described without quantum mechanics. Corrections
to the force ﬁeld parameters can at least partly overcome these issues. The exclusion
of QM and bond formation and breaking also means that no chemical reactions like
enzymatic catalysis or pH dependent change in the protonation state of a protein
can take place.
MD force ﬁelds are inherently approximations of real life mechanics. All simula-
tion results depend on the selection of an accurate force ﬁeld for the application in
question. The force ﬁelds are pair-additive, which means that all non-bonded forces
result from the sum of non-bonded pairwise interactions. The PBCs may also cause
problems if not addressed as mentioned earlier. The sizes and time scales achievable
by MD simulations still remain very limited compared to experiment. This is both
one of the advantages and downsides of MD as it oﬀers resolutions that can not be
achieved otherwise, but as new systems get bigger and the simulations longer, the
costs of running a simulation also increase.
The MARTINI model has a very wide range of potential applications in MD
simulations, but the force ﬁeld has some important limitations that should be kept
in mind. First of all, the model is parameterized for the ﬂuid phase, and works best
in such systems. It was originally parameterized especially for lipid and surfactant
systems [148], and only later extended for other molecules. The behavior of solid
and gas phase appears too stable with respect to the ﬂuid phase, and thus the
thermodynamic behavior of these phases at liquid interfaces should be interpreted
with care [144].
The use of the CG model accelerates diﬀusion of molecules compared to experi-
mental data by an average conversion factor of 4 [144], which has to be taken into
account when comparing the time scales of reactions with AA or experimental data.
The time step should be chosen between 20 and 40 fs to use the model as eﬀectively
as possible. The CG energy landscape is highly simpliﬁed compared to AA, which
leads to increased sampling speed at the cost of a loss of detail [144]. Too short time
step undermines the eﬃciency of the model and is waste of computing time.
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When considering the simulation of proteins and peptides, the biggest shortcom-
ing of the MARTINI model is that the secondary structure transformations are
not possible. The secondary structure is ﬁxed by the use of a dihedral potential
energy function. On the other hand, the changes in the tertiary structure of pro-
teins have been shown to be quite realistic [145]. The original parameterization of
the MARTINI model has been shown to signiﬁcantly overestimate the strength of
proteinprotein interactions [164]. This can be compensated by down-scaling the
non-bonded interaction parameters between protein particle types.
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4. PROTEIN STRUCTURE PREDICTION AND
MODELING
This chapter gives a very short introduction to the basics of protein structure and the
most common methods used in protein structure prediction. MD simulations are a
method that can be used to predict and verify novel protein structures [130]. Protein
models can be based on experimental data or amino acid sequence homogeneity. The
ﬁrst part of this chapter is based mostly on references [21,165,166], and the protein
structure prediction and protein modeling on reference [130].
4.1 Basics of Protein Structure
The structure of a protein deﬁnes its function in biological systems. The protein
structure is often described at four levels: primary, secondary, tertiary, and qua-
ternary structure. The shape of a protein is deﬁned by its primary structure, i.e.
the amino acid sequence. The primary structure describes all the covalent bonds
linking amino acid residues in polypeptide chains, which includes mainly the pep-
tide bonds in the polypeptide backbone and the disulﬁde bonds between pairs of
cysteine residues. The sequence of the 20 naturally occurring amino acids is essen-
tial for the three-dimensional structure and correct functioning of a protein. Single
point mutation in the sequence can alter the structure and make the protein partly
or completely inactive.
The secondary structure refers to commonly occurring stable local arrangements
of amino acids forming regular structural patterns. The two most commonly oc-
curring types of secondary structures are α-helix and β-sheets. The formation of
these structures is driven by hydrogen bonding in the protein backbone. Secondary
structure prediction is one of the challenges in deﬁning the correct tertiary struc-
ture. Homology modeling and multiple sequence alignment can be used to identify
common patterns in the protein sequence resulting in these local arrangements [167].
The tertiary structure of a folded protein describes the whole three-dimensional
arrangement of all the residues in a polypeptide. Folding of a protein to its native
conformation is driven by many types of covalent and noncovalent forces and in-
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teractions, and may involve other proteins called chaperones. The forces include,
in addition to the ones involved in the primary and secondary structure, hydrogen
bonding of the protein side chains, clustering and burying of nonpolar residues to
the inside of the protein by hydrophobic interactions, and electrostatic interactions
between oppositely charged groups.
The quaternary structure describes three-dimensional arrangement of a protein
consisting of two or more polypeptide subunits. The subunits of an oligomer are
often held together by noncovalent interactions and they can be easily dissociated
by treatment with denaturing agents. The subunits can be identical or diﬀerent
depending on the protein and thus similar or varying tertiary structures and con-
formational states.
4.2 Protein Structure Prediction
Protein structure prediction attempts to deﬁne a realistic model for the 3D structure
of the protein by comparing it to pre-existing protein structures, or alternatively by
computationally solving the folding of smaller secondary and tertiary structures in a
protein. The challenge is to explore the whole conformational space of the molecule
in order to identify the most appropriate, i.e. lowest energy, structures from the
immense number of possibilities. The global minimum in the energy function is
assumed to represent the native state of the structure of the molecule.
Protein structure prediction methods can be roughly divided into two main
groups: comparative modeling and computational modeling. The ﬁrst step in build-
ing a new model for a protein is to check if any protein structure databases, e.g. the
Protein Data Bank (PDB) [168], contain known homologous sequences of similar
proteins that can be used for homology modeling. If there are no known homolo-
gous proteins, but a structurally similar fold is recognized, a method called protein
threading is an option. If neither comparative modeling method is suitable for the
structure prediction or the structure needs to be reﬁned, computational modeling
can solve relatively small protein structures. Ab initio protein structure predic-
tion methods try to solve the tertiary structure of a protein using only the primary
sequence of amino acids.
Homology Modeling Proteins in the same family share similarities in the 3D
structure as well as function, originating mostly from the homology of their primary
structures [169]. Comparative modeling uses these structural similarities between
proteins to construct a 3D-model based on the known structures of one or more
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related template proteins [170]. There are four steps in constructing a homology
model for an unknown protein structure: template selection, sequence alignment,
model construction, and model assessment [170]. The template selection is the most
critical step in homology modeling, and careful assessment needs to be done to ﬁnd
the best ﬁtting structure. The simplest method is to use an automated program
like FASTA [171] or BLAST [172] to do pairwise sequence alignment over known
entries in protein databases. A sequence homology of over 30% is a requirement
for correct homology modeling, but values of over 40% sequence identity have been
found to produce more reliable structural models for new proteins [170]. Pairwise
comparison might overlook some trends occurring in the structures. If more than one
protein in the same family are known, a more accurate way for template searching
is to use multiple sequence alignment tools, like PSI-BLAST [173], that can produce
improved models from larger clusters of homologous proteins [167].
After template selection the sequences need to be properly aligned before model
construction. One of the most commonly used programs for multiple sequence align-
ment is CLUSTAL [82, 174]. The 3D-model for the target protein is constructed
based on the alignment using one of the three model generation methods: rigid
body assembly, segment matching, and satisfaction of spacial restrains [170]. The
ﬁrst method assembles together rigid bodies or conserved structural fragments taken
from the template proteins found in the alignment phase. In the second method the
target protein sequence is aligned in shorter segments to several templates from
PDB, and each segment is modeled based on the best segment homology. The
third method generates a series of geometrical criteria from the templates, which
are used in conjunction with an optimization procedure to determine a structure of
the target. Accuracies of the methods are relatively similar, and template selection
and sequence alignment have a much larger impact on the model accuracy. Note-
worthy software used for protein structure homology modeling include e.g. MOD-
ELLER [175], SWISS-MODEL [176] and ROSETTA [177].
The initial structures obtained from comparative modeling can be of high energy
and require energy minimization to reﬁne the ﬁnal structure. After construction
the model needs to be evaluated. Most of the analysis can be done automatically
using computer programs that examine the structure for common ﬂaws in the fold
and free energies. If discrepancies between the developed model and experimental
data occur, the model needs to be reﬁned until the best structure has been found.
As experimental resolution and evaluation methods have improved over the years,
thousands of submitted protein structures in the PDB have become obsolete [178].
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Protein Threading Protein threading or fold recognition is a template-based
method that is used if there are no known homologous proteins or the sequence
homology is below 30%. Homology modeling aligns the target sequence to one or
multiple template sequences whereas protein threading aligns the target sequence to
template structures to ﬁnd similar protein folds. Protein threading is based on the
assumption that there is a limited number of possible protein folds in nature, and
the amino acid sequence implies a preference for diﬀerent structural environments
in the folds. According to the Structural Classiﬁcation of Proteins (SCOP) [179]
and the Class, Architecture, Topology, Homology (CATH) [180] databases there are
approximately 1400 known protein folds, and majority of new proteins submitted to
PDB are structurally related to the ones already in the database with deﬁned folds.
In protein threading the sequence is compared to a library of all known secondary
and tertiary structures to get the best alignment of the sequence to a template. An
objective scoring function is used to sort out the best sequencestructure alignment
from all the possibilities. The function takes into account factors like amino acid
preference for solvent (hydrophobicity), amino acid preference for a particular sec-
ondary structures and preferred interactions between residues, like ionic bonds and
disulﬁdes. Even after careful setup and consideration of the scoring function, protein
threading has a high possibility of producing only incorrect structures.
Ab initio Protein Structure Prediction The use of computational protein
structure prediction methods is limited by the requirement for vast computational
resources, and has been restricted to small proteins of a few dozen residues and tar-
geted small sections of proteins observed to fold rapidly [181]. MD simulations are
one of the computational methods used to predict and study new protein structures,
but their ultimate shortcomings limit their use. Correct protein folding simulations
require time-scales ranging from microseconds to several milliseconds, with a force
ﬁeld that describes correctly all the intermediate unfolded and misfolded confor-
mations, reproduces the true potential energy surfaces of proteins, and minimizes
all cumulative errors of long simulations [181]. Representative sampling of protein
folding calls for numerous repetitions to characterize the heterogeneous folding pro-
cesses.
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5. SIMULATION MODELS AND ANALYSIS
METHODS
In this thesis the interactions between SP-B and the main pulmonary surfactant
phospholipids were studied using MD simulations described in chapter 3. The prepa-
ration of the simulation systems from protein model reﬁning to simulation system
construction, and the basics of the analysis methods used are covered in this chapter.
5.1 System Preparation
A good structural model is a requirement for a successful simulation. Based on ini-
tial simulation results with the original homology model for the SP-B multidimeric
oligomers from [6] we decided to further reﬁne the protein structure to better match
experimental results. The systems were built to study SP-B's interactions with
the pulmonary surfactant phospholipids. Due to their amphipathic nature, phos-
pholipids assemble spontaneously into lipid aggregates, like micelles and liposomes.
The best way to study any lipid-speciﬁc interaction sites in the structure of SP-B
is to conduct lipid self-assembly (SA) simulations. These self-assembly studies work
as a starting point for any other proteinlipid interaction simulations as they oﬀer
a potential starting conformation for the permanently membrane-bound SP-B in
monolayers or bilayers.
5.1.1 Modeling
Neither high resolution structural model nor molecular mechanism of SP-B function
have existed until recently. An experimental study by Olmeda et al. [6] revealed
the presence of 10 nm ring-shaped multidimeric oligomer states of SP-B, based on
atomic force and electron microscopy. A multiple sequence alignment with SP-B and
saposin B proteins was done, and two 3D-models for dimers of SP-B were constructed
based on the experimentally observed states of saposin B [6]. This resulted in the
open and closed conformations for the dimers of SP-B (see Fig. 2.9), and ﬁnally
the pentamers and hexamers of dimers. These oligomeric states were evaluated to
best comply both to the observed size of the assemblies and the intra-chain C48
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disulﬁde bonds and adjacent E51R52' and E52R51' salt bridges stabilizing the
supradimeric complex.
For clarity a second distinction between two overlapping structural units of SP-B
dimers needs to be done: a functional dimer (Dimf) and a disulﬁde-bridged dimer
(Dimc). The functional dimer refers to a dimer formed by two SP-B monomers
in a conformation akin to that of saposin B dimer. An inner hydrophobic cavity
possibly responsible for lipid interaction is located between the monomers alike to
the lipid binding pocket found in saposin B [182]. The disulﬁde-bridged dimer, or
covalent dimer, refers to the structure commonly extracted in previous experiments,
where the monomers are connected by a disulﬁde bridge at C48. Thus the covalent
SP-B dimer contains one monomer from each adjacent functional dimers of the
supradimeric structure.
A series of model reﬁnement steps were conducted based on extensive initial MD
simulation results with the original structures from [6]. We aimed to generate all-
atom supradimeric oligomer models of various sizes that would:
(i) contain the SAPLIP-like functional dimer structure as a basic structural unit
in either open or closed conformation
(ii) have the interface conductive to formation of the inter-chain disulﬁde and salt
bridges
(iii) have the putative lipid binding site facing towards the central pore of the ring.
We used Rosetta's [183, 184] symmetric docking protocol with restraints on the
distances between the interface forming residues to generate decoys that satisfy
(ii). We later sorted these models based on their total score, clustered them, and
extracted cluster centers that satisfy (iii) as ﬁnal models. A hexamer of dimers
(6mer) was selected as the main multi-dimeric oligomer to be used in the simulations
based on initial results and reference [6]. The SP-B structures used in this study
are shown in Fig. 5.1.
5.1.2 SP-B Systems
Three phospholipid compositions were selected for the lipid self-assembly (SA) and
monolayer simulations, the characteristics of which can be seen in Table 5.1. The
physiological lipid composition (PHYS) was derived from previous studies [2, 24],
while the simplest DPPC and CHOL (DC) composition contained the same molar
fraction of CHOL as the PHYS composition. A total of three diﬀerent conformations
of the modeled SP-B were used to study the protein's interactions with diﬀerent
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Figure 5.1 SP-B structures used in the study. Up left: the atomistic and the coarse-
grained Dimf . Up right: the atomistic and coarse-grained Dimc. Below: the structure
of the SP-B hexamer of dimers with phospholipids inside the lipid binding pockets. The
SP-B oligomer forms a ring with a hyrdophobic central pore in the middle. The membrane
binding residues in the N- and the C-termini are located at the outer rim of the initial
structure. The lipid binding pockets of the functional dimers are facing the central pore.
phospholids. These structures were the Dimc, the Dimf , and the SP-B hexamer of
dimers (6mer) (see Fig. 5.1 and Table 5.2).
Table 5.1 Lipid compositions in simulation systems. DC refers to a lipid composition
of DPPC and cholesterol [185], EQ to an equal mole fraction of all four lipids, and PHYS
represents an approximation of the physiological lipid composition of the pulmonary sur-
factant [2, 24].
Name DPPC POPC POPG CHOL
(mol-%) (mol-%) (mol-%) (mol-%)
DC 90 10
EQ 25 25 25 25
PHYS 50 25 15 10
SP-B lipid self-assembly In the preparation of the lipid self-assembly simulation
systems, 24 independent starting conformations with each protein structure and
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lipid composition were built by inserting the lipids randomly into the simulation
box with the gmx insert-molecules GROMACS program. All dimer systems had
a total of 300 lipids and 12000 CG water beads, and 6mer systems were built with
1100 lipids and 33000 water beads. In all systems the NaCl concentration was
kept at a physiological value of 150mM. A total of 216 self-assembly simulations
were performed, 144 with the functional dimer (Dimf) and covalent dimer (Dimc)
structures, and 72 simulations with the SP-B hexamer of dimers (6mer) structure
(see Table 5.2). Each system was simulated for 2.5 µs.
SP-B monolayer systems The monolayers were constructed with the INSANE
script [146]. The area per lipid (APL) was varied and four values were chosen to
represent diﬀerent compression states of the pulmonary surfactant. These values
were 52.5, 55, 57.5, and 60Å
2
. APL values below 52.5Å
2
resulted in folding (initial
state of collapse) of the monolayer before protein contact, and values of over 60Å
2
resulted in spontaneous formation of holes in the monolayers. The protein was
inserted between the monolayers into the water phase, after which the water beads
were removed in small batches (500 water beads) from the systems followed by a
short 10 ns simulation step with the protein position restrained. NaCl concentration
was kept at physiological value of 150mM. This resulted in systems where SP-B is in
contact with two monolayers, one on each side of the protein, with a varying distance
between the monolayers. Four inter-monolayer distances were chosen and selected
from each set of systems with diﬀerent APL. Three repetitions of each constructed
monolayer system were simulated each for a total of 25.0 µs (see Table 5.2).
5.2 Simulation Parameters
All simulations were performed using the GROMACS package version 5.1.2 [128]
and the coarse-grained MARTINI force ﬁeld [145,149,150]. An energy minimization
step with the steepest descent algorithm was performed before running the produc-
tion simulations. The self-assembly systems were equilibrated in two steps before
production runs: ﬁrst at 310K under NVT conditions with an integration time step
of 25 fs for 200 ps, then under NPT conditions at a constant 1 bar pressure controlled
with the isotropic Berendsen barostat [158] for 200 ps. Other conditions were kept
the same. The production runs were simulated using an integration time step of
25 fs at a reference temperature of 310K controlled with the v-rescale method [161]
with a time constant of 1.0 ps. Separate heat baths for the protein, the lipids, and
the solvent were used. A reference pressure of 1 bar was used and controlled with
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Table 5.2 A list of the simulation systems in this study. Dimf is the functional SP-B
dimer, Dimc is the covalently bound SP-B dimer, 6mer is the hexamer of SP-B dimers, SA
is lipid self-assembly simulation, mono is monolayer interaction simulation, and the lipid
compositions are as in Table 5.1. * Four APLs, with four monolayer distances, each with
three repetitions.
Protein SA/mono Lipid composition Repetitions Time (µs)
Dimf SA DC 24 2.5
Dimf SA EQ 24 2.5
Dimf SA PHYS 24 2.5
Dimc SA DC 24 2.5
Dimc SA EQ 24 2.5
Dimc SA PHYS 24 2.5
6mer SA DC 24 2.5
6mer SA EQ 24 2.5
6mer SA PHYS 24 2.5
6mer mono PHYS 48 * 25.0
the isotropic ParrinelloRahman barostat [162] with a time constant of 12.0 ps. All
bonds were constrained using the LINCS algorithm [186]. Production simulations
of the monolayer systems were performed at 310K under NVT conditions with an
integration time step of 25 fs.
5.3 Analysis Methods
Lipid Contact Frequency The number of frames in which any bead of the lipid
is within a 0.6 nm cut-oﬀ distance of any bead of each protein residue is counted and
divided by the total number of frames to get the lipid contact frequency for each
protein residue. This analysis was performed for each repetition, 24 per self-assembly
systems, and 3 for monolayer simulations, and normalized by dividing by the total
number of frames in all repetitions. The mean of the results and the standard errors
(SE) are presented. An additional normalization based on the relative concentration
of each lipid type was performed in PHYS system. The analysis is implemented in
a TCL script to be used with VMD [187].
Inter-Monolayer Distance The distance between the two monolayers on both
sides of the 6mer was measured to select corresponding systems from diﬀerent APL
simulations. The distance of the monolayers was determined as the average distance
of PO4 beads in the CG phospholipids, representing the phosphate group of the
lipids, over the course of the simulation. The GROMACS program gmx density
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was used to compute the partial densities of the particles across the box, and the
inter-monolayer distance was calculated from the plotted data.
Area Per Lipid APL was determined for the monolayers and bilayers with
APL =
Amembrane
Nlipids/2
, (5.1)
where Amembrane is the area of the monolayer or bilayer, and Nlipids is the total
number of lipids in both monolayers or leaﬂets of the bilayer.
Density Maps The lateral 2D number density maps of each lipid species were de-
termined using the GROMACS program gmx densmap to show the average density
of lipids in the monolayers around the protein. The density maps were calculated
separately for each monolayer to compare the protein's ability to reorganize surfac-
tant lipids upon adsorption to the surface, and to ﬁnd speciﬁc interaction sites for
the lipids in the protein structure.
The density maps were determined as a average over the repetitions. Before
calculating the density maps, a proper translation and rotation was applied to each
frame to superimpose the protein to the same reference structure. The heatmaps
were normalized per lipid type to allow for comparison between diﬀerent lipids. Four
APL values with four monolayer distances allowed the evaluation of their eﬀect in
the lateral distribution of lipids around the protein.
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6. RESULTS AND DISCUSSION
In this thesis, the speciﬁc lipid interactions and membrane binding of our new model
for the structure of pulmonary surfactant protein B (SP-B) were studied. The func-
tional investigation of pulmonary surfactant requires a delineation of lipid-protein
interactions, which can be achieved by using molecular dynamics simulations. SP-B
is an essential part of the human pulmonary surfactant and its functionality, yet its
structure and molecular mechanism of function have remained elusive until recently.
Thus, the study of the lipid-protein interactions is necessary for understanding the
function of SP-B in the pulmonary surfactant.
To evaluate the eﬀect of diﬀerent oligomer structures of SP-B, we performed a
total of 216 lipid self-assembly MD simulations using three SP-B structures in three
lipid compositions. Two forms of SP-B dimers, the covalent dimer (Dimc) and the
functional dimer (Dimf), and a SP-B hexamer of dimers (6mer) were studied (see
Fig. 5.1). We chose lipid compositions, which contained DPPC and cholesterol
(DC), equal mole fractions of the four main surfactant lipids (EQ), and a compo-
sition similar to the physiological structure of pulmonary surfactant (PHYS) (see
Table 5.1). Additionally, the eﬀect of SP-B on the lateral lipid reorganization of
surfactant lipids in SP-B coupled monolayers at diﬀerent compression states were
studied by performing a total of 48 MD simulations (see Table 5.2 for a list of
all simulation systems). The nomenclature used in this chapter is summed up in
Fig. 6.1.
This chapter focuses on the possible lipid binding conformations and orientations
of SP-B dimers and hexamer of dimers in membranes. In the latter part of the
chapter, SP-B's observed membrane lipid perturbing eﬀect is discussed as a possible
molecular mechanism of function for the protein. All molecular images and analyses
were prepared using VMD [187] and MATLABR©.
6.1 Lipid Self-Assembly Simulations
The MARTINI force ﬁeld was originally parameterized for lipid and surfactant sys-
tems [148] and has been since extended to include other biomolecules, such as pro-
teins [145]. As amphiphilic molecules, lipids have a tendency to spontaneously form
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Figure 6.1 Reference structures. The buried hydrophobic residues are located on the
inner face of the monomers in the functional dimer, and are shielded from water by the op-
posing monomer of the Dimf . The residues in the membrane binding sites of the individual
Dimf structures are shown in red, and the residues in the membrane perturbing sites are
shown in blue. The residues of the membrane binding site of the Dimf are located in the
N- and C-terminal helical structures, and the membrane perturbing site is located near the
turn in the primary structure, approximately from residue V31 to Y53. The lipid binding
pocket of the Dimf is located between the SP-B monomers and is lined with the buried hy-
drophobic residues. The membrane binding surface and the membrane perturbing surface
of the SP-B hexamer of dimers are directed towards opposing membranes or monolayers
in the orientation of SP-B membrane binding suggested by our results. The hydrophobic
central pore of the SP-B hexamer of dimers is enclosed by the lipid perturbing sites of the
individual dimers.
diﬀerent lamellar and non-lamellar phases in water [188]. Thus, we performed lipid
self-assembly simulations to study the lipid interaction of the membrane associated
SP-B. The formation of micellar aggregates, mostly spherical micelles and bilayer
discs, was observed to be very rapid in the self-assembly systems, with SP-B parti-
tioning exclusively into the lipid phase.
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6.1.1 SP-B Dimers Have Two Distinctly Diﬀerent Binding
Conﬁgurations
We studied the lipid contact frequency of each residue in the SP-B structure to ﬁnd
speciﬁc lipid interaction sites in the dimers. The overall lipid contact frequency
represents the average interaction time of a residue with any lipid in the system
during the simulation time, while the lipid-speciﬁc contact frequency diﬀerentiates
lipids by type. One protein residue can be in contact with more than one type of
lipid in each frame, while contact with two lipids of the same type is counted as one.
Thus the lipid-speciﬁc contact frequency results can be interpreted as a preference
towards a speciﬁc type of a lipid, but not directly as a proportion of all contacts.
Also the results of the contact frequency analysis show lipid-speciﬁc interaction sites
in the structure of the protein. On the other hand, the overall lipid contact frequency
results show preferences for the membrane binding orientation of the dimers.
Two distinctly diﬀerent lipid binding conﬁgurations were observed between the co-
valent (Dimc) and the functional (Dimf) variations of the SP-B dimers (see Figs. 6.2
and 6.4). All three lipid compositions showed similar overall lipid contact frequen-
cies with individual residues (see Figs. 6.3 and 6.5). The diﬀerences seen in lipid
contact frequencies between the Dimc and Dimf structures arise from the orientation
of the protein at the surface of the lipid interface.
Covalent dimers In the self-assembly simulations, the Dimc structure is pre-
dominantly oriented towards the lipids in a binding mode shown in Fig. 6.2. SP-B
consists of a large fraction of hydrophobic residues, which reside on both faces of the
extended SP-B monomer. In the Dimf structure most of the hydrophobic residues
are buried within the cavity between the monomers while the rest of the hydropho-
bic residues in the helical N- and C-terminal portions of the protein are involved in
membrane binding (see Fig. 6.1). In the beginning of the simulation of the Dimc
structure, these buried hydrophobic residues are exposed to the water phase. Our
results show that with all tested lipid compositions, the Dimc is at the surface of a
bilayer disc oriented with these buried hydrophobic residues towards the lipids (see
Fig. 6.3).
In our simulations Dimc partitions to the edge of the bilayer discs formed during
the lipid self-assembly. The covalently linked dimer attains an orientation in which
it interacts with both leaﬂets of the bilayer disc (see Fig. 6.2). As previously
mentioned, there are two proposed theoretical molecular models for the topology
of SP-B in phospholipid membranes [73]. A transmembrane orientation of SP-B
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Figure 6.2 Lipid binding conﬁguration of the Dimc shows a possible orientation of binding
with lipids for the SP-B dimer based on the self-assembly simulations. Dimc binds to the
edge of a bicelle in a transmembrane orientation. PHYS lipid composition, DPPC in grey,
POPC in blue, POPG in red, and cholesterol in green.
dimers and the interaction of SP-B with the inner core of bilayers at the edge of
membrane discs has been suggested in some studies [71,111,189] (see also Fig. 2.7).
Our results suggest that such a topology for the SP-B dimer is possible, but due to
the limited number of lipids in the system, the transmembrane orientation of the
Dimc in lamellar membranes could not be studied. However, majority of experiments
imply a more superﬁcial binding mode of SP-B [67,83,87].
In previous MD simulation studies with monomers and dimers of SP-B, two mem-
brane binding orientations of SP-B on the surface of monolayers and bilayers have
been demonstrated [102,104,112]. These studies showed that SP-B can adopt either
an extended or a bent conformation, depending on which face of the protein is ori-
ented towards the water phase and which one towards the lipids. Our results show
a membrane binding orientation of Dimc, where the conformation of each monomer
of Dimc is similar to the extended conformation of SP-B monomers and dimers pre-
viously shown by Baoukina et al. [102, 104] or the open conformation suggested by
Khatami et al. [112].
The bent conformation is denoted as the active form of SP-B monomers that
triggers fusion and perturbations in adjacent membranes [104], while the extended
conformation has been shown to induce local curvature in lipid monolayers at higher
surface pressures in MD simulations [102]. The bent conformation of the SP-B
monomer is more like the monomers in our models for the Dimf and the SP-B
hexamer of dimers. Thus the speciﬁc lipid interactions and lipid binding orientations
of Dimf are of more interest when studying the higher oligomers.
6.1. Lipid Self-Assembly Simulations 51
0.5
1
0.5
1
L
ip
id
co
nt
ac
t
fr
eq
ue
nc
y
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75
0.5
1
Residue number
0
20
40
60
0
20
40
A
ve
ra
ge
di
st
an
ce
of
a
re
si
du
e
fr
om
th
e
ce
nt
er
(Å
)
0
20
40
Figure 6.3 The overall lipid contact frequency per residue of Dimc in lipid self-assembly
simulations. DC, EQ, and PHYS lipid compositions, respectively. The average distance
of a residue from the center of the 6mer measured from the crystal structure. Results
calculated as an average of 24 repetitions each, error as SE.
Functional dimers Dimf was found to bind lipids in a characteristic orientation
with two main lipid interaction sites in the structure (see Fig. 6.4). The membrane
binding orientation of Dimf was independent of the lipid composition, and similar
overall lipid contact frequencies were observed with each system (see Fig. 6.5).
The four main helical secondary structures in SP-B can be seen in the graph (see
e.g. Fig. 6.5) for the average distance of a residue from the center of a 6mer as
incremental steps at residues from W9 to I22, from A30 to C35, from A42 to G63,
and from Q68 to V74. Residues further from the hypothetical center of the 6mer are
at the outer face of the monomer, while residues closer to the center of the 6mer are
buried within the hydrophobic cavity formed by two adjoined monomers. Thus, the
lipid binding orientation of the protein could also be deduced from the diﬀerence in
trends in lipid binding residues between Dimc and Dimf in Figs. 6.3 and 6.5.
Based on our results, the structure of Dimf has two lipid interaction sites: the
membrane binding and themembrane perturbing site (see Figs. 6.1 and 6.4). Fig. 6.1
shows the structure of Dimf , where the residues of the membrane binding site and the
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Figure 6.4 Lipid binding conﬁguration of Dimf shows a possible orientation of binding
with lipids for the SP-B dimer based on the SA simulations. Dimf has two preferential lipid
interaction sites on opposite sides of the dimer. A cholesterol molecule (green) is within
the lipid binding pocket, which can be seen as a shadow in the center of the protein.
membrane perturbing site are highlighted. The membrane binding sites of individual
Dimf reside at the outer rim of the SP-B hexamer of dimers, while the membrane
perturbing sites are facing the center of the hexamer. The experimentally deter-
mined important membrane binding residues are located in the membrane binding
site. On the other hand, the membrane perturbing site is unique to our model for
Dimf and the SP-B hexamer of dimers. A characteristic feature of the membrane
perturbing site observed in the self-assembly simulations was the insertion of lipids
in the lipid binding pocket, as seen in Fig. 6.4. Further studies with the SP-B hex-
amer of dimers show the membrane perturbing eﬀects of the site, discussed further
in section 6.2.2.
The membrane binding site of Dimf refers to the residues located in the N- and
the C-termini of the monomers that have been shown to be signiﬁcant for the correct
membrane binding SP-B [94,96]. Based on the overall lipid contact frequency results
with Dimf with diﬀerent the lipid compositions (see Fig. 6.5), the trends seen in
the lipid binding residues of the N-terminus match the proposed lipid binding ori-
entation of SP-B found in experiments [3, 96]. In addition, the lipid binding of the
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Figure 6.5 The overall lipid contact frequency per residue of Dimf in lipid self-assembly
simulations. DC, EQ, and PHYS lipid compositions, respectively. The average distance
of a residue from the center of the 6mer measured from the crystal structure. Results
calculated as an average of 24 repetitions each, error as SE.
C-terminus in our Dimf model is in agreement with experimental and MD simulation
studies [88]. The membrane binding site of Dimf consists of the hydrophobic and
positively charged residues in the N- and C-terminal helical structures positioned
parallel to the membrane, and the six unstructured hydrophobic residues in the N-
terminus. Thus, the suggested orientation of membrane binding of the Dimf model
is in compliance with the superﬁcial membrane interaction topology of SP-B [73].
The lipid-speciﬁc interaction contact frequency for each lipid type was analyzed
for the Dimf structure with the EQ lipid composition in the self-assembly simulations
for the last 2µs of the simulation, as shown in Fig. 6.6. The results show speciﬁc
lipid preference for POPG and cholesterol for certain residues in the previously men-
tioned interaction sites. POPG shows preferential interaction with the hydrophobic
and positively charged membrane binding residues in the N- and C-terminal regions
of the protein compared to DPPC or POPC. The positive residues R12, K16, and
R17 in the N-terminal region and R72 in the C-terminal region increase the lipid-
speciﬁc interaction frequency of these residues due to the electrostatic interactions
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Figure 6.6 Dimf lipid-speciﬁc contact frequency per residue in EQ lipid composition
with DPPC, POPC, POPG, and CHOL, respectively. The average distance of a residue
from the center of the 6mer measured from the crystal structure. Results calculated as an
average of 24 repetitions each, error as SE.
between the anionic phospholipids and the positive residues. An increase in contact
frequency with POPG is also seen in the membrane binding sequence from F1 to
P6, and with W9. Our results suggest that anionic lipids, especially PG, have an
important role in the interaction of the pulmonary surfactant with SP-B, as shown
by experiments [72,190].
The membrane perturbing site of the Dimf structure is located near the lipid
binding pocket of the functional SP-B dimer. To our knowledge, this lipid interaction
site in our model for the Dimf has not been described in previous experimental
studies, and its existence is based purely on the homology model with saposin B.
The lipid perturbing site of Dimf is located at the turn in the primary structure,
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approximately from V31 to Y53, and includes a high proportion of hydrophobic
residues (see Fig. 2.6). The lipid-speciﬁc contact frequencies shown in Fig. 6.6
show a preference of interaction for this site with cholesterol. This could be due to a
preference of the adjacent lipid binding pocket towards cholesterol. The speciﬁc lipid
interactions described here for the Dimf structure indicates a preferential orientation
of membrane binding for the SP-B hexamer of dimers and any other possible higher
oligomers.
6.1.2 SP-B Hexamer of Dimers Has a Lipid Interaction Site
in the Central Pore
Within the 2.5µs simulation time, the lipid self-assembly simulations with the SP-
B hexamer of dimers lead to the formation of both small micellar aggregates, like
micelles, bilayer discs and vesicles, and to the formation of lamellar bilayers (see
Figs. 6.7 and 6.8). The SP-B hexamer of dimers remained associated with the
lipid phase in all simulations, as predicted by the self-assembly simulation results
with SP-B dimers. Table 6.1 lists the occurrence of diﬀerent lipid structures in the
simulated systems. Bilayer discs or bicelles were most common with 51 out of 72
simulations. A total of 18 out of these 51 systems with bilayer discs resulted in
almost complete bilayers (see Fig 6.7), where SP-B partitioned to the edges of the
adjacent membranes, preventing the formation of a complete bilayer. Thus, these
systems were calculated as formation of bilayer discs, but are shown also separately
as the number of incomplete bilayers out of systems with bilayer discs or bicelles in
Table 6.1.
Table 6.1 Formation of diﬀerent lipid structures in the self-assembly simulations with
the SP-B hexamer of dimers. The formation of bilayer discs or bicelles was most common.
Incomplete bilayers refer to bilayer discs, which were close to attaining a bilayer structure.
Bilayers were observed in a total of 17 simulations out of 72.
Name Bilayer discs / (Incomplete Vesicles Bilayers
bicelles bilayers)
DC 22 (8) 2
EQ 13 (4) 2 9
PHYS 16 (6) 2 6
Total (72) 51 (18) 4 17
In the example system in Fig. 6.8, a bilayer assembled within the ﬁrst 500ns
and maintained an average APL of 63.5Å
2
after assembly for the rest of the 2.5µs
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Figure 6.7 Example membrane binding conﬁgurations of SP-B hexamer of dimers in lipid
self-assembly simulations. Left ﬁgure above shows a system where the protein is between
two bicelles with a micellar aggregate in the central pore of the ring. Right ﬁgure above
shows an example of an almost complete bilayer. The ﬁgure below shows a vesicle with a
bound SP-B hexamer of dimers.
simulation time. The protein remained attached to the membrane while allowing the
exchange of a few lipids between the bilayer and the attached micelle through the
central pore of the SP-B hexamer of dimers. The formation of a complete bilayer was
not observed in the majority of the self-assembly simulations during the simulation
time, as shown in Table 6.1.
The self-assembly simulations showed two preferential lipid interaction sites in
the SP-B hexamer of dimers, which are equivalent to the sites seen with the Dimf
structure (see Figs. 6.5 and 6.9). The lipid composition of the systems did not sig-
niﬁcantly aﬀect the overall lipid contact frequency of individual residues. The same
lipid interacting residues are involved with membrane binding and lipid interaction
in the Dimf and the 6mer structures, which in the case of the SP-B hexamer of dimers
results in a conﬁguration where lipids are within the central pore of the ring (see
Figs. 6.1 and 6.8). The lipid-speciﬁc contact frequency results (see Appendix B)
further show a preference of cholesterol partitioning into the central pore, while
POPG interacted preferentially with the membrane binding residues in the N- and
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Figure 6.8 SP-B hexamer of dimers connected to a bilayer and a micelle formed in an
SA simulation with PHYS lipid composition. Cholesterol (green) partitioned preferentially
into the central pore of the hexamer ring in self-assembly simulations (see Appendix B).
C-termini of SP-B. The central pore of the SP-B hexamer of dimers is enclosed by
the lipid perturbing sites of the individual dimers. Thus, the lipid binding pockets
of the functional dimers are also facing towards the center and may participate in
the transfer of lipids across the central pore. Fig. 6.1 recaps these lipid interaction
sites in our model for the SP-B hexamer of dimers.
Based on the self-assembly simulation results with our Dimf and 6mer structures
in diﬀerent lipid compositions, the transfer of lipids between membranes, one of
the most important roles of SP-B in the pulmonary surfactant, occurs through the
central pore. In the self-assembly simulations with the SP-B hexamer of dimers,
we observed an orientation of membrane binding where the axis of the central pore
is parallel to the membrane normal (see Fig. 6.8). In this orientation, the active
membrane perturbing sites as well as the membrane binding residues on the opposing
side of the structure are in contact with their respective membranes. This orientation
of membrane binding for the SP-B oligomers is also supported by experimental
data [6]. The hydrophobic central pore of the oligomer ring is necessary for the
molecular mechanism of function of the SP-B implicated by our results.
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Figure 6.9 SP-B hexamer of dimers overall lipid contact frequency per residue in self-
assembly simulations with DC, EQ, and PHYS lipid compositions, respectively. The aver-
age distance of a residue from the center of the 6mer measured from the crystal structure.
Results calculated as an average of 24 repetitions each, error as SE.
6.2 Monolayer Simulations
The monolayer systems were built to study the eﬀect of SP-B hexamer of dimers on
monomolecular ﬁlms. Pulmonary surfactant forms a monolayer ﬁlm at the airliquid
interface of the alveoli. We decided that the simplest and computationally least ex-
pensive method to study the eﬀect of SP-B hexamer of dimers on monolayers was to
build systems, where the monolayers are coupled by the protein in the middle. This
experimental simulation setup would allow the study of membrane binding, lipid in-
teractions, and other possible eﬀects of the SP-B hexamer of dimers on monolayers.
Diﬀerent compression states of the pulmonary surfactant were studied by selecting
four areas per lipid (APL) i.e. surface pressures. All monolayers were identical in
the number and type of lipids. Thus, diﬀerences seen in the ﬁgures are caused by
the SP-B hexamer of dimers upon interaction.
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6.2.1 SP-B Induces Lateral Lipid Reorganization in Coupled
Monolayers
The distance between the selected monolayers ranged from 2.7nm to 3.8 nm in ap-
proximately 0.3 nm steps. In most systems this range was optimal for the interaction
of SP-B with both monolayers. The protein remained attached on both sides while a
conformational change in the orientation of the dimers turned the membrane bind-
ing residues in conjunction towards one monolayer, and the membrane perturbing
residues towards the opposite. The area per lipid (APL) did not aﬀect the binding
of SP-B with the monolayers.
When forming the monolayers, we used diﬀerent APLs to investigate how the
compressing of the monolayer can eﬀect its interaction with SP-B. The APL of the
system aﬀected the integrity of the monolayers. The largest APL of 60Å
2
caused
the formation of holes in the monolayers in some simulations. We assume that the
holes in the monolayers are mainly caused by the force ﬁeld's inability to properly
account for the energetic penalty of exposing a pure surface, i.e. the surface tension
(∼30mN/m in MARTINI [149] vs. the experimental value of 70mN/m in pure
water), as similar behavior was observed in the preparation of the monolayers with
APLs of over 60Å
2
, even before the addition of SP-B into the system. On the other
hand, the formation of proteolipid pores in membranes has been reported in the
presence of SP-B [100]. Thus, some of the repetitions of the 60Å
2
APL monolayer
simulations might not represent realistic number densities in the monolayer plane
and are mostly omitted from the comparison of the results in this section. Based
on our results, monolayers with our PHYS lipid composition were not suitable to be
simulated with an APL of over 60Å
2
with the MARTINI force ﬁeld.
The lateral lipid distribution results for two representative systems with 52.5Å
2
and 57.5Å
2
APL are shown in Figs. 6.10 and 6.11, respectively. The results are
presented as an average of three repetitions and normalized per lipid type in the
PHYS lipid composition. These results show the lateral reorganization of POPG
and cholesterol around SP-B in all systems. This lipid speciﬁcity was independent
of the APL of the monolayers and can be seen in all systems with all four APLs. The
lateral lipid distribution results for the rest of the systems are included in Appendix
A for reference.
The membrane binding residues caused the enrichment of POPG around the area
of the monolayer in contact with the protein, seen as a ring of higher POPG density
in the upper monoalyer in Figs. 6.10 and 6.11. This preference for POPG was
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also observed in the lipid-speciﬁc contact frequency results shown in section 6.1.1.
Thus, POPG is likely to have an important role in the correct binding of SP-B to
pulmonary surfactant membranes. POPG also binds preferentially to the membrane
perturbing site of SP-B, which can be seen as an increased density in and around
the central pore on the lower monolayer in Figs. 6.10 and 6.11.
Figure 6.10 Lateral lipid distribution in a 52.5Å2 APL system, represented by num-
ber density maps for the upper (left) and the lower (right) monolayer. The distance of
the monolayers was 3.6 nm. Results are normalized per lipid type to show speciﬁc lipid
interactions with SP-B.
Our model for the SP-B hexamer of dimers induced lateral organization of POPG
that complies to experimental results [63, 72]. The enhanced POPG interactions
with the membrane binding surface (see Fig. 6.1) of the SP-B oligomer on the
upper monolayer in the ﬁgures likely plays a role in establishing the correct bind-
ing mode with the pulmonary surfactant and directionality of lipid transfer (see
Figs. 6.10 and 6.11). POPG interaction is also enhanced on the membrane per-
turbing surface of the protein (see Fig. 6.1), seen in the ﬁgures on the lower mono-
layer. The membrane binding surface has ﬁve or six positively charged residues per
monomer (R12, K16, R17, R64, R72, and R76) facing the membrane, while there
is one positively charged residue per monomer (R36) in the membrane perturbing
surface. The positions of these charged residues in the SP-B hexamer of dimers af-
fected the lateral distribution of POPG in our monolayer simulations. These results
are in concordance with the unusually high concentration of anionic phospholipids
in the pulmonary surfactant compared to other mammalian membranes [3, 24].
Cholesterol partitioned preferentially into the area of perturbed lipids in the cen-
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tral pore of the protein as shown in Figs. 6.10 and 6.11 in the lower monolayers.
The 52.5Å
2
APL system showed an especially high density of CHOL in the central
pore in the perturbed area of the monolayer, whereas in the 57.5Å
2
APL system,
an increased density of CHOL was observed also inside the lipid binding pockets
of the dimers, which can be seen as local clusters around the perturbed area. In
the other systems CHOL clustered into these two sites, but the APL did not aﬀect
the preference for either (see appendix A). Based on our resuls, cholesterol seems
an important component in the function of SP-B in the surfactant, although it is
excluded from some clinical surfactants used in SRT even in the precence of the
protein [10].
Figure 6.11 Lateral lipid distribution in a 57.5Å2 APL system, represented by num-
ber density maps for the upper (left) and the lower (right) monolayer. The distance of
the monolayers was 3.4 nm. Results are normalized per lipid type to show speciﬁc lipid
interactions with SP-B.
The compression state of the monolayer aﬀects the packing of the lipids, which
leads to a more ordered Lc phase at low molecular areas. In our simulations, the
compression state of the monolayers did not substantially aﬀect the lateral distribu-
tion of lipids around SP-B. Similar trends in POPG and cholesterol clustering were
observed in all systems. Thus, we propose that cholesterol as well as POPG are
involved in the molecular mechanism of the function of the protein, and especially
POPG is important in the binding of the SP-B oligomer to membranes.
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6.2.2 SP-B Mediates Lipid Perturbations in Monolayers
In the monolayer simulations, SP-B bound to the monolayers on both sides of the
protein. One monolayer was in contact with the membrane binding surface of the
SP-B hexamer of dimers structure, and the other with the membrane perturbing
surface of the protein. Upon interaction, the membrane perturbing surface of SP-B
caused perturbations and lipid protrusions of variable size to the monolayer in con-
tact with the protein membrane perturbing surface. In some systems, SP-B induced
the formation of a larger lipid protrusion or a lipid neck to the monolayer, as shown
in Figs. 6.12 and 6.13. This protrusion was dependent on the conformational
changes in the protein structure during the simulation, and occurred on the side
of the membrane perturbing surface of SP-B in contact with the monolayer. The
extent of the lipid neck observed in the simulations varied from small protrusions in
the monolayer to an almost complete contact between the lipids of opposite mono-
layers. In 25 µs each system was simulated for, we did not observe lipid exchange
between the monolayers. This is likely due to the lack of a driving force, such as a
concentration or stress gradient.
Figure 6.12 Lipid perturbations in monolayers caused by SP-B. Cholesterol (green)
partitions preferentially into the hydrophobic central pore of the SP-B hexamer of dimers.
Here, the APL is equal to 57.5Å2.
Formation of the lipid neck was more likely to occur with lower APL, but smaller
lipid protrusions were observed with all tested APLs. Thus, the applied surface pres-
sure may cause larger protrusions in the monolayers mediated by SP-B, which would
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push lipids through the protein during compression of the monolayer in exhalation.
Fig. 6.8 shows a possible intermediate state of lipid ﬂow through SP-B that could
form when enough surface pressure is applied to the system. It has been suggested
that SP-B promotes connections between surfactant membranes and the monolayer
at the airliquid interface [3, 22]. These SP-B mediated connections (see Fig. 2.8)
could allow favorable partitioning of oxygen into the continuous lipid phase, which
could permit rapid O2 diﬀusion through the hydrophobic core of the membranes,
as suggested by Olmeda et al. [4]. The formation and the stability of these small
lipid reservoirs connected to surfactant monolayers or membranes should be further
studied.
As mentioned earlier, higher APL caused the formation of small holes is the
monolayers (see Fig. 6.13). There is experimental evidence of SP-B causing pore
formation in membranes [100], but in our case we concluded that the holes are more
probably caused by the force ﬁeld's inability to account for the surface tension. On
the other hand, the membrane poration activity of SP-B has been suggested to be
highly indicative of the oligomeric structure of the protein [100]. Thus some form of
pore or hole formation could be characteristic to our model for the SP-B hexamer
of dimers.
Figure 6.13 High APL caused the formation of holes in monolayers with SP-B. Choles-
terol (green) partitioned preferentially in the perturbed lipids in the central pore. Here,
the APL is equal to 60Å2.
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7. CONCLUSIONS
The aim of this thesis was to study the speciﬁc lipid interactions and th binding
of SP-B in pulmonary surfactant membranes. To this end, we used coarse-grained
MARTINI MD simulations. Due to the extreme hydrophobicity and diﬃculty of
extraction, only low resolution homology models for monomers and dimers of SP-B
exist in the literature. A recent study revealed the presence of a ring-shaped multi-
dimeric SP-B structure in pulmonary surfactant, and provided a novel structure for
a SP-B hexamer of dimers [6]. This study concentrates in our reﬁned model for the
structure of the SP-B hexamer of dimers that is based on the above-mentioned struc-
ture. To our knowledge, this study is pioneering concerning the higher oligomers of
SP-B. All previous MD studies have concentrated on monomers and covalent dimers
of SP-B [102,104,112], or even smaller portions of the protein [88,191]. These studies
have given some insight to the possible molecular mechanism of function of SP-B,
but have not provided an unambiguous protein model derived from homology mod-
eling.
The focus of this thesis was on the speciﬁc lipid interactions of SP-B, which will
work as a basis for further studies concerning the larger oligomeric structures of
SP-B. Two types of systems were simulated for this purpose: lipid self-assembly
in the presence of the protein, and monolayers coupled by SP-B in a sandwich-like
conformation. A total of three protein structures were studied to ﬁnd out the correct
orientation of membrane binding. These structures were the covalently bound dimer,
the functional dimer that is the basis for the multidimeric oligomer, and our reﬁned
SP-B hexamer of dimers.
The results showed that the dimers have two preferential lipid binding conﬁgura-
tions. The covalent dimer prefers a planar orientation on the surface of a membrane
and was observed to partition to the edge of bilayer discs. On the other hand,
the functional dimer had two membrane binding sites on the opposing sides of the
structure. We call these sites the membrane binding site and the membrane per-
turbing site. The membrane binding site corresponds to the N- and C-terminal
helices in SP-B that have been shown to orient parallel to membranes [88,191] and
contain the residues essential for the correct binding and orientation of SP-B in
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surfactant membranes [11, 92]. The membrane perturbing site is on the opposing
side of the dimer, adjacent to the lipid binding pocket. The results show that the
membrane perturbing site causes protrusions and smaller perturbations in the af-
fected membrane. Residues in the membrane binding site showed preference for
POPG, whereas cholesterol was enriched in the membrane perturbing site and the
lipid binding pocket.
Self-assembly simulations with the SP-B hexamer of dimers showed a possible pla-
nar orientation of membrane binding, which would allow the ﬂow of lipids through
the hydrophobic central pore of the oligomer ring, also suggested by Olmeda et
al. [6]. These results indicate a possible model for the molecular function for the
higher oligomers of SP-B that has not been described earlier. SP-B caused similar
perturbations in the coupled monolayers, which lead to the formation of a lipid neck
inside the central pore. SP-B induced lateral lipid reorganization in the monolayers
and showed preference for POPG and cholesterol. POPG clustered near the mem-
brane binding and the membrane perturbing sites on opposite monoalyers indicating
its importance for the binding and function for the protein, while cholesterol was
found in increased concentrations in the central pore and the lipid binding pockets
of the SP-B hexamer of dimers.
This study can work as a basis for many future MD simulation studies on higher
oligomeric structures of SP-B. The implicated molecular model of function for the
protein should be further studied, and the systems extended to e.g. coupled bilayers,
monolayers connected to lipid reservoirs, and other biologically relevant bilayer and
monolayer setups. The simulations should also be repeated in atomistic detail to
validate the results and to gain better molecular view of the interactions. Free energy
proﬁles of the SP-B membrane binding process would provide more detail of the
correct orientation of binding and depth of insertion into membranes. Furthermore,
the study of SP-B could provide information about the molecular mechanism of
action for all of the SAPLIP proteins.
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APPENDIX A. LATERAL LIPID
REORGANIZATION FIGURES
Figure 1 APL 52.5Å2, average inter-monolayer distance 3.2 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
Figure 2 APL 52.5Å2, average inter-monolayer distance 3.5 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
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Figure 3 APL 52.5Å2, average inter-monolayer distance 3.5 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
Figure 4 APL 55Å2, average inter-monolayer distance 2.7 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
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Figure 5 APL 55Å2, average inter-monolayer distance 3.1 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
Figure 6 APL 55Å2, average inter-monolayer distance 3.3 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
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Figure 7 APL 55Å2, average inter-monolayer distance 3.6 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
Figure 8 APL 57.5Å2, average inter-monolayer distance 3.1 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
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Figure 9 APL 57.5Å2, average inter-monolayer distance 3.4 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
Figure 10 APL 57.5Å2, average inter-monolayer distance 3.5 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
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Figure 11 APL 60Å2, average inter-monolayer distance 2.7 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
Figure 12 APL 60Å2, average inter-monolayer distance 3.0 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
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Figure 13 APL 60Å2, average inter-monolayer distance 3.3 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
Figure 14 APL 60Å2, average inter-monolayer distance 3.6 nm. Left: lipids of the upper
monolayer facing the membrane binding surface of the protein, right: lipids of the lower
monolayer facing the membrane perturbing surface of the protein. Results are normalized
per lipid type to show speciﬁc lipid interactions with SP-B.
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FREQUENCY OF SP-B HEXAMER OF DIMERS
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Figure 15 SP-B hexamer of dimers lipid-speciﬁc lipid contact frequency per residue in EQ
lipid composition with DPPC, POPC, POPG, and CHOL, respectively. Results calculated
as an average of 24 repetitions, error as SE.
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Figure 16 SP-B hexamer of dimers lipid-speciﬁc lipid contact frequency per residue in
PHYS lipid composition with DPPC, POPC, POPG, and CHOL, respectively. Results
calculated as an average of 24 repetitions, error as SE.
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Figure 17 Normalized SP-B hexamer of dimers lipid-speciﬁc lipid contact frequency per
residue in PHYS lipid composition with DPPC, POPC, POPG, and CHOL, respectively.
Results calculated as an average of 24 repetitions and normalized based on the relative
concentration of each lipid type, error as SE.
